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Lysophosphatidic acid (LPA) belongs to a class of extracellular lipid signaling molecules.  In 
the vasculature, LPA may regulate platelet activation and modulate endothelial and 
smooth muscle cell function.  LPA has therefore been proposed as a mediator of 
cardiovascular disease. 
The bulk of circulating LPA is produced from plasma lysophosphatidylcholine (LPC) by 
autotaxin (ATX), a secreted lysophospholipase D (lysoPLD).  Early studies suggest that 
some of the production of circulating LPA is platelet-dependent.  ATX possesses an N-
terminal somatomedin B-like domain suggesting the hypothesis that ATX interacts with 
platelet integrins which may localize ATX to substrate in the membrane and/or alter the 
catalytic activity of ATX.  Using static adhesion and soluble binding assays we found that 
ATX does indeed bind to platelets and cultured mammalian cells in an integrin-dependent 
manner which is blocked by integrin function-blocking peptides and antibodies.  This 
binding increases both the activity of ATX and localization of its product, LPA, to the 
platelet/cell membrane. 
LPA is generally stimulatory to human platelets although platelets from a small population 
of donors are refractory to LPA stimulation.  Likewise LPA is inhibitory to murine platelets.  
We previously found that LPA receptor pan-antagonists reduce agonist-induced platelet 
activation, and partial stimulation of LPA5 specifically increases platelet activation in 
humans.  Since both LPA5 and LPA4 are present at significant levels in human platelets, 
we hypothesized that LPA4 is responsible for an inhibitory pathway and LPA5 is 
responsible for an inhibitory pathway.  We used mice deficient in LPA4 to test this model.  
Isolated platelet function tests revealed no major difference between lpa4-/- mice 
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compared with WT mice although lpa4-/- mice were more prone to FeCl3-induced 
thrombosis.  Paradoxically, chimeric mice reconstituted with lpa4-/- deficient bone 
marrow derived cells were protected from thrombosis.  These discrepancies may be 
explained by involvement of endothelial cells and the relative scarcity of LPA receptors in 
murine platelets compared with human platelets. 
Taken together, these results demonstrate two critical regulators of LPA signaling and 
open up new avenues to further our understanding of atherothrombosis. 
KEYWORDS:  lysophosphatidic acid, platelet, autotaxin, signaling, integrin, G protein-
coupled receptor 
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CHAPTER 1:  INTRODUCTION 
Diseases of the vascular system continue to be the most common cause of mortality in 
the United States with over 30% of deaths in the year 2007 being a result of heart 
disease or cerebrovascular disease1.  As such, there has been much interest in 
characterizing vascular physiology and pathophysiology.  The role of bioactive lipids in 
mediating vascular physiology and pathophysiology is becoming increasingly understood 
and appreciated.  Of these, the major bioactive lipids that act on cell surface receptors 
are sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA), both of which 
circulate in the blood.  In the vasculature, LPA may regulate endothelial and smooth 
muscle cell function as well platelet function.  In addition, there is evidence suggesting 
that platelets play a vital role in production of circulating LPA raising the question of 
whether locally produced platelet-derived LPA may have a role in modulating acute and 
chronic cardiovascular insults.  To that end, the work presented herein addresses novel 
aspects of the role of platelets in LPA generation and the role of LPA in platelet 
signaling. 
ROLE OF PLATELETS IN NORMAL PHYSIOLOGY 
Platelets are small, anucelate cell particles that are derived from bone marrow 
megakaryocytes.  Once activated, they function to maintain the integrity of injured 
vasculature by forming an initial hemostatic plug at the site of injury and subsequently 
aiding in the initiation of the coagulation cascade.  The hallmarks of platelet activation 
  
 
2 
include adhesion, shape change, granule secretion, and cohesion (aggregation).  These 
sequelae form the foundation of the role that platelets play both physiologically or 
pathologically. 
Platelets form intricate and complex interactions with other blood cells and vascular 
cells.  Most platelets are circulating in a resting state exhibiting a small discoid 
morphology.  Even in this quiescent condition, interactions with other cells are of 
paramount importance.  The resting state is maintained largely by platelet inhibitors 
such as nitric oxide (NO) and prostaglandin I2 (PGI2) which are derived from healthy 
endothelial cells2, 3.  These inhibitors in general mediate increases in intraplatelet cyclic 
nucleoside monophosphates such as cyclic adenosine monophosphate (cAMP) which is 
refractory to platelet activation2, 4. The normal inhibition that healthy, intact 
endothelium exerts on platelets is perturbed during injury of the vessel. 
Both collagen and von Willebrand factor (vWF) are present in the subendothelial matrix 
and are subseqnuently exposed when a vessel is damaged.  Initial interactions of 
platelets with the subendothelial matrix occur through platelet receptor complex 
glycoprotein (GP) Ib-IX-V which binds to VW.  Both vWF and GPIb-IX-V are required for 
adhesion of platelet under high shear conditions such as what is encountered in the 
arterial system5.  Following adhesion, activation of the platelet itself occurs.  Activation 
of platelets is elicited by many platelet agonists in vitro, but in the context of adhesion in 
vivo, it is mostly initiated by collagen which signals primarily through GPVI6 and 
thrombin (factor IIa) which signals primarily through protease-activated receptor 1 
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(PAR1) and PAR47, 8; thrombin itself is generated at sites of injury by the activity of tissue 
factor and other coagulation factors. 
Collagen and thrombin, as with other platelet agonists, effect activation by signaling 
through a number of different pathways.  Ultimately these pathways converge leading 
to the sequelae mentioned previously.  Actin reorganization and polymerization leads to 
shape change which transforms the platelet from a discoid shape to their activated 
conformation9 allowing them to spread to cover the injured area as well as increase 
contact with other platelets/cells.  Exocytosis of α and dense granules result in secretion 
of numerous agents including adenosine diphosphate (ADP), serotonin, fibrinogen, 
fibronectin, etc.10  Activated platelets furthermore produce the platelet agonist 
thromboxane A2 (TXA2)11 as well as thrombin12, a platelet agonist and an essential 
molecule in the coagulation cascade.  Each of these substances promotes the growth of 
the hemostatic plug largely by recruiting and activating additional platelets.  Fibrinogen 
is a multivalent ligand that can bind to αIIbβ313, an integrin receptor only present on 
platelets.  Integrins exist in low-affinity and high-affinity states which may be regulated 
by intracellular processes; in platelets integrins transition to the high-affinity 
conformation during platelet activation allowing them to binding tightly with ligands 
such  fibrinogen.  Cross-linking of fibrinogen with multiple platelets allows them to 
cohere to each other resulting in aggregation which also allows the thrombus to grow13.  
αIIbβ3 further associates with platelet cytoskeletal elements14 and over time contractile 
elements act on the cytoskeleton to allow the clot to retract15.  Each of these hallmarks 
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– adhesion, shape change, granule secretion, and aggregation – allow platelets to 
perform their best-characterized function, hemostasis. 
Outside of their traditional roles in hemostasis, it is becoming increasingly clear that 
platelets also play a role in other physiological processes such as angiogenesis, microbial 
defense, and inflammation.  Platelets contain a number of substances that promote 
angiogenesis in their granular and membranous arsenal including a number of growth 
factors, CD40 ligand (CD40 is located on endothelial cells), phospholipids, matrix 
metalloproteases, etc.16  Angiogenesis inhibitors are also  found in platelet granules 
including angiostatin, platelet factor 4 (PF4), endostatin, and transforming growth factor 
(TGF) β 16. Platelets also directly interact with the endothelium17 suggesting this could 
also be a regulatory point for angiogenesis.  Furthermore, both ex vivo and in vivo 
experimental evidence has demonstrated that platelets promote angiogenesis18. 
In the context of microbial responses, platelets possess a number of immune-related 
receptors including receptors for the Fc domain of immunoglobulins (FcγRII)19 and 
various adhesive receptors20.  They are furthermore able to interact directly or indirectly 
with bacteria21, 22, viruses23, protozoa24, and fungi25.  Many bacteria have been shown to 
elicit platelet activation and aggregation21, and platelets are even capable of 
phagocytosis26 or aiding in the immobilization of pathogens within platelet aggregates22.  
Aside from interaction with microbes, platelets also intricately interact with other 
inflammatory cells both directly and indirectly.  Activated platelets interact directly with 
leukocytes and secrete chemokines which recruit leukocytes to sites of injury16.  
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Platelets also indirectly facilitate recruitment of leukocytes as they induce increased 
expression of adhesive molecules and secretion of chemokines by endothelial cells27.  
Platelets are clearly an important player in the inflammatory process. 
While the physiological role of platelets has largely been associated with hemostasis, 
platelets are more and more becoming appreciated for the integral role they play in 
other functions such as angiogenesis, immunity, and inflammation in both normal 
physiology and in the context of human disease. 
ROLE OF PLATELETS IN CARDIOVASCULAR DISEASE 
Historically, much of the impetus for studying platelet function in the context of human 
disease was in the context compromised hemostasis (ie, non-functional or absent 
platelets).  The association between hemorrhagic disorders and thrombocytopenia has 
been observed since the late 19th century.  Subsequently the role of platelets in 
hemostasis became clearer once it was determined that bleeding in thrombocytopenic 
individuals could be corrected by whole blood infusion28.  Later platelet transfusion was 
found to likewise be therapeutic in treating such disorders29.  Bleeding diatheses could 
additionally be caused by inherent deficiencies in platelet function even in the presence 
of normal platelet counts.  These were largely the incentives that led to the discovery 
and characterization of integrin αIIbβ3 (deficient in Glanzmann Thrombasthenia), vWF 
(deficient in von Willebrand disease), and the GPIb-IX-V complex (deficient in Bernard-
Soulier Syndrome). 
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While inherent or acquired deficiencies in platelet function or number are still real and 
relevant health concerns for a number of people, the broader health issue which 
concerns platelets is thrombosis rather than deficiencies in hemostasis.  Compared with 
hemostasis, which is essentially the cessation of bleeding by the formation of a 
thrombus, thrombosis indicates the formation of a thrombus that occludes a blood 
vessel.  The acute occurrence of a thrombosis, as seen in a myocardial or cerebral 
infarction, is a potentially catastrophic occurrence that largely follows years of chronic 
vascular disease, namely atherosclerosis.  The central role of platelets in these disease 
states is apparent by the prevalence of antiplatelet therapeutics in use such as 
clopidogrel and aspirin. While platelets are clearly involved in these particular 
thrombotic endpoints, they also play central roles in the progression of such diseases. 
During the past century, populations in developed parts of the world have grown 
progressively older, leading to increased incidence of chronic disease.  Atherosclerosis, a 
chronic vascular disease, has reached epidemic levels in the developed world.  The main 
risk factors are largely summed up by what is termed the metabolic syndrome and 
include diabetes mellitus, hypertension, dyslipidemia, obesity, etc. (all of which are 
steadily increasing in the United States).  Simply stated, atherosclerosis is characterized 
by fatty lesions that insidiously accumulate and grow in the intima of large- and 
medium-sized arteries.  The generally accepted view of its pathogenesis is the response-
to-injury hypothesis which was first suggested by Ross and Glomset in 197330.  In this 
model, subtle and progressive endothelial damage results in an immune response and 
the subsequent accumulation of immune cells (eg, monocyte-derived macrophages), 
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lipids, etc.  The response-to-injury model is supported by the predilection of portions of 
vessels that are subjected to turbulent blood flow to develop atheromas.  Early lesions 
are known simply as fatty streaks and consist mostly of the pathognomonic foam cells, 
lipid-laden macrophages.  These progress to involve infiltration of smooth muscle cells, 
immune cells, etc.  Atherogenesis is therefore considered a chronic inflammatory 
process. 
Most commonly platelets are thought to play a pathological role during acute coronary 
events following decades of atherogenesis.  While this is true, platelets also play an 
important role in the injury response model of atherogenesis itself which could well be 
attributed to their inflammatory role described in the preceding section.  Platelets are 
the earliest cell-types to accumulate at the site of injury.  Upon their activation, they in 
turn can stimulate endothelial cells to express adhesion molecules and chemotactic 
molecules that recruit monocytes to the site of injury resulting in an inflammatory 
response27, 31.  Platelets themselves secrete a host of chemokines upon activation via 
release of granular components and have adhesive molecules to interact directly with 
dendritic cells and monocytes16.  In turn, monocyte-derived macrophages that have 
infiltrated the intima accumulate lipid forming foam cells whose presence are 
pathognomonic for atherosclerosis. 
LIPIDS IN CARDIOVASCULAR DISEASE 
Research in the role of lipids in atherogenesis began to accelerate in the 1970s with an 
observation in the Framingham study that indicated an association between early onset 
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heart disease and total serum cholesterol32.  During this same period, Brown and 
Goldstein identified that familial hypercholesterolemia, a genetic disorder associated 
with accelerated atherogenesis and coronary artery disease, was caused by a disorder of 
the low density lipoprotein (LDL) receptor33.  The LDL receptor normally allows for the 
uptake and degradation of LDL-associated cholesterol in the plasma.  Paradoxically, 
although LDL receptor-mediated uptake of cholesterol by most cells was abolished in 
individuals with homozygous familial hypercholesterolemia, cholesterol could still 
accumulate in macrophages producing foam cells; this phenomenon led to a search for 
chemically modified LDL particles whose uptake into macrophages was via a mechanism 
independent of LDL receptor-mediated uptake34.  It was found that cultured endothelial 
cells were capable of modifying native LDL such that its uptake by macrophages was 
greatly enhanced35, 36, a modification that was later characterized as oxidative in 
nature37.  Scavenger receptors on macrophages were identified to facilitate this uptake 
of modified LDL35, 38.  In addition to their propensity to form foam cells oxidatively-
modified forms of LDL were also found to be cytotoxic to a variety of cells39-41 which 
made them an attractive target in the response-to-injury model of atherogenesis.   
Native LDL particles themselves are heterogeneous consisting of a core of entirely 
hydrophobic lipids (especially cholesteryl esters) surrounded by an outer layer 
consisting of lipids with hydrophilic groups such as phospholipids, lysophospholipids, 
and unesterified cholesterol as well as a single apolipoprotein B-100 (apoB)42.  The 
precise nature of in vivo LDL oxidation is incompletely understood, and mechanisms of 
oxidizing LDL in vitro vary widely among researchers.  Not surprisingly, the term oxidized 
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LDL (oxLDL) does not refer to a single entity, but rather it refers a group of particles all 
with different lipid makeup and different degrees of oxidation.  In general, LDL is 
considered extensively oxidized when it loses its LDL receptor recognition determinants 
and gains recognition determinants for scavenger receptors.  Such receptor affinities are 
attributed to modification of the apoB protein itself43 as well as oxidative modification 
of the lipid component of LDL where short-chained phosphatidylcholine derivatives also 
serve as scavenger receptor ligands44.  Oxidative modification of LDL also drastically 
increases the relative abundance of lysophospholipids37, 45 which will be discussed in the 
following section. 
LYSOPHOSPHOLIPID DISTRIBUTION AND METABOLISM 
While roles of lipids in cellular communication were not apparent in earlier decades, it is 
now recognized that there are clearly many bioactive lipids that play roles in cell 
signaling.  These include intracellular signaling molecules such as diacylglycerol (DAG), 
nuclear receptor ligands such as the steroid hormones, and G protein-coupled receptor 
(GPCR) ligands such as the prostaglandins and lysophospholipids.  Lysophospholipids are 
derivatives of glycerophospholipids or sphingophospholipids that contain only one radyl 
hydrocarbon chain (typically a fatty acyl group) (Figure 1.1).  The major types of 
bioactive lysophospholipids with GPCR-mediated effects are LPA and S1P, and each of 
these types is composed of species with fatty acyl chains of varying lengths and degrees 
of saturation.  Lysophosphatidylcholine (LPC) also has biologic activity in some systems, 
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although it is unclear if LPC acts directly through selective receptors or serves as a 
precursor for a primary mediator, such as LPA or a released fatty acid.     
These lysophospholipids are found ubiquitously in plasma, peritoneal fluid, 
cerebrospinal fluid, seminal/follicular fluid, etc.  At least 15 molecular species of LPA and 
both S1P and its dihydro derivative are found in the circulation of humans and mice at 
physiologic levels.  Cumulatively, the species of LPA and S1P are present in the 
circulation at micromolar concentrations in humans and mice46-49 compared with the 
much more abundant LPC at concentrations on the order of 100 µM50.  These 
lysophospholipids largely exist associated with plasma proteins and lipoproteins42, 51.  In 
regards to their metabolism, it appears that plasma lysophospholipids (especially LPA) 
turn over rather quickly52 with their plasma levels being tightly regulated by their 
production and degradation.  Both extracellular LPA and S1P are primarily removed 
from circulation by dephosphorylation to monoacylglycerol (MAG) and sphingosine 
respectively.  This removal is accomplished by the broad-acting integral membrane class 
of enzymes known as the lipid phosphate phosphatases (LPPs), and S1P is additionally 
hydrolyzed by the S1P-selective phosphatases53.  Genetic deletions of LPP3 in particular 
is embryonically lethal due to defects in early vascular development and patterning (ie, 
chorio-allantoic placenta and yolk sac vasculature)54, a phenotype that is reproduced if 
the deletion is limited to endothelial cells (Panchatcharam et al, unpublished). 
In contrast to their degradation, the routes of production for S1P and LPA differ as LPA is 
formed from hydrolysis of circulating lysophospholipids and S1P is formed by 
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phosphorylation of sphingosine.  In the case of LPA, the primary route of production in 
blood plasma involves hydrolysis of LPC.  The source of circulating LPC is from two 
general pathways.  The first is lecithin cholesterol acyltransferase (LCAT) which transfers 
an acyl group from phosphatidylcholine to cholesterol forming LPC and cholesteryl 
esters.  The second mostly includes secreted phospholipase A2 (PLA2) and lipoprotein-
associated PLA2s (both the LCAT and PLA2 pathways are reviewed by Levitan et al42).  As 
will be discussed in Chapter 2, secreted enzymes with PLA1 activity also generate an LPA 
with the fatty acyl group in the sn-2 position which may then undergo acyl transfer to 
the sn-1 position55.  Hydrolysis of LPC to LPA involves the lysophospholipase D (lysoPLD) 
enzyme autotaxin (ATX) which is a member of the ectonucleotide 
pyrophosphatase/phosphodiesterase (ENPP) family.  In this family of enzymes, ATX 
possesses a unique ability to hydrolyze lipid substrates (specifically lysophospholipid 
substrates).  Inactivation of the Enpp2 gene encoding ATX in mice (Enpp2-/-) is 
embryonically lethal with severe defects in vascular maturation56, 57.  Enpp2+/- mice 
have half-normal circulating levels of ATX and LPA56, 57, and pharmacologic inhibition of 
ATX results in rapid and substantial drops in circulating LPA52.  Transgenic 
overexpression of Enpp2 using the α1-anti-trypsin inhibitor promoter to drive 
expression in liver increases plasma ATX/lysoPLD activity and LPA levels49.  These 
findings establish that ATX is a primary regulator of LPA levels in the blood.  A summary 
of LPC and LPA metabolism in the plasma is shown in Figure 1.2. 
Several lines of evidence also implicate platelets as important participants in LPA 
production in the circulation. LPA levels in serum prepared from platelet-rich plasma 
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(PRP) are 5- to 10-fold higher than in platelet-poor plasma (PPP)58-60, which suggests 
that activated platelets play an active role in LPA production during clotting. 
Experimental induction of thrombocytopenia in rats, using an anti-platelet antibody, 
decreases the production of LPA in serum by almost 50%58.  Similarly, treatment of mice 
with a small molecule inhibitor of the platelet fibrinogen receptor, integrin αIIbβ3, 
causes thrombocytopenia and significantly decreases circulating LPA61. 
S1P is primarily generated by phosphorylation of sphingosine catalyzed by 2 sphingosine 
kinases (SPHK1 and SPHK2) and is degraded reversibly by dephosphorylation or cleaved 
nonreversibly by S1P lyase62.  Combined deficiency of Sphk1 and Sphk2 is lethal 
embryonically; however, an inducible deletion of Sphk1 in Sphk2-/- pups generates 
animals that survive to adulthood with no detectable S1P in plasma63.  Transplant of 
normal bone marrow cells into these Sphk1- and Sphk2-deficient animals restores 
plasma S1P levels, establishing a role for marrow-derived cells in maintaining circulating 
S1P levels63.  Because platelets contain Sphk but lack S1P lyase, they can synthesize and 
accumulate S1P64.  Upon activation, platelets release stored S1P and until recently were 
assumed to be the source for the bulk of circulating S1P.  However, cell reconstitution 
experiments indicated that red blood cells, rather than platelets, appear to be the major 
hematopoietic source for plasma S1P63.  Although on an individual basis a platelet 
contains more S1P than a red blood cell, red blood counts (~ 5 x 1012 / L) are 
approximately 25-fold higher than platelet counts (~ 0.2 x 1012 / L), so that the total 
amount of S1P in red blood cells vastly exceeds that in platelets.  In humans, S1P levels 
linearly correlate with hematocrit, providing further support that red blood cells are a 
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primary source of plasma S1P65, 66.  In addition to platelets and red blood cells, other 
vascular components, including the endothelium, also contribute to circulating S1P 
levels67. 
LYSOPHOSPHOLIPID RECEPTORS 
Even prior to the discovery of lysophospholipids receptors, the bioactivity of LPA and 
S1P had been indicated which included reports on the effects of lysophospholipids on 
vasopression and blood pressure68, 69, contraction of smooth muscle in different organ 
systems70, 71, and platelet activation72, 73.  By this point relationships of lysophospholipids 
with health and disease were of interest, and the field was ripe for the discovery of 
lysophospholipid-specific receptors.  The first of these was a GPCR discovered in 1996 
that showed LPA binding and LPA-dependent activity74; it was eventually termed LPA1.   
Subsequently several other GPCRs specific to either LPA or S1P would be characterized 
and account for all or at least most of lysophospholipid bioactivity; there have, however, 
been some suggestions of LPA signaling through peroxisome proliferator-activated 
receptor γ (PPAR γ)75.  The initial receptors identified were closely homologous and 
denoted endothelial cell differentiation gene (EDG) receptors although they were 
subsequently renamed to more rationally reflect their respective ligands.  Of these, 
there are five S1P receptors (designated S1P1-5) and three LPA receptors (designated 
LPA1-3).  At least two (and for the purposes of this dissertation, three) other LPA 
receptors (LPA4-6) had been identified that are divergent from the EDG-family LPA 
receptors showing more sequence homology to nucleotide-selective receptors than to 
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the earlier lysophospholipid receptors (Figure 1.3); LPA4 and LPA6 were formerly 
classified in purinergic family of receptors P2Y9 and P2Y5 respectively). 
The lysophospholipid receptors are ubiquitous in tissues and signal via canonical G 
protein pathways (their signaling pathways have generally been identified with 
expression in various mammalian cell lines).  Of the S1P receptors, the first to be 
identified was S1P1 (originally designated EDG1)76 which couples only to Gi/o.  It is 
broadly expressed in adult tissues77 and critical during embryonic development as 
genetic deletion resulted in embryonic lethality with problems in vascular maturation78 
and neurogenesis79.  S1P2 and S1P3 are also expressed widely, but unlike S1P1, genetic 
deletions are not embryonically lethal and have relatively mild phenotypes80, 81.  They 
are also able to couple more promiscuously with different G protein receptors82.  There 
is evidence of cooperativity among these three S1P receptors as embryonic lethality 
occurs earlier and with a more severe phenotype when an S1P1 deletion is coupled with 
an S1P2 and/or S1P3 deletion83.  S1P4 and S1P5 have a much more narrow expression 
pattern with S1P4 expressed primarily in lymphocytes84 and S1P5 in the central nervous 
system and spleen85.  S1P5 knockout animals have defects in natural killer cell 
trafficking.86  (S1P4 deletion has not been reported.) 
As with all of the S1P receptors, the first three LPA receptors described are members of 
the EDG family of receptors.  LPA1-3 are all widely expressed and can all couple to 
various G proteins.  Genetic deletions of any of these receptors is not uniformly 
embryonically lethal87.  The signaling in different receptors is also dependent on 
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individual LPA species as cellular responses vary depending on fatty acyl length and 
degrees of saturation.  For instance unsaturated LPA species are more potent at 
activating most receptors88-92.  LPA1 appears to play an important role in the developing 
nervous system.  The most obvious phenotype of a deletion of this receptor is 
craniofactial defects, defects in Schwann cells, and about 50% mortality with small size 
(the latter are mostly attributed to suckling defects)93.   Deletion of LPA2 yields viable 
animals with no overt phenotype, and double deletion of both LPA1 and LPA2 does not 
produce any additional defects94.  Likewise LPA3 deletion does not produce an overt 
abnormality except that there are reduced litter sizes and delays in embryo 
implantation95, 96. 
Even prior to the discovery of LPA4, it was becoming increasingly clear that there were 
additional LPA signaling mechanisms as platelet aggregation and certain mitogenic 
responses to LPA were increasingly recognized as EDG family-independent97-99.  As 
mentioned earlier, discovery of the LPA4 receptor heralded a new class of structurally 
divergent non-EDG family LPA receptors.  Despite its structural differences, the 
dissociation constant for LPA4 and its ligand was comparable to that for the other 
receptors100.  Deletions of LPA4 have been reported by three different groups:  one 
genetic knockout had no obvious phenotype101, a small hairpin ribonucleic acid (shRNA) 
LPA4 knockdown animal showed increased osteogenesis102, and a separate genetic 
knockout showed reduced survival with hemorrhaging and vascular defects103.  These 
results can be partially explained by strain differences of the knockouts and a possible 
redundancy of the receptors.  It also suggests a role for LPA4 in vascular development 
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which is consistent with the phenotype of ATX knockout animals described above.  
Following the discovery of LPA4, two other non-EDG family LPA receptors were 
described, LPA5104, 105 and LPA688.  Genetic deletions of these receptors have not yet 
been described, and their definitive functions are still speculative. 
ROLE OF LYSOPHOSPHOLIPIDS IN CARDIOVASCULAR HEALTH AND DISEASE 
As mentioned above, lysophospholipids are present at relevant concentrations in the 
plasma.  They are capable of effecting cellular responses via GPCRs, and moreover, most 
every cell type related to the cardiovasculature has been shown to have a response to 
LPA and S1P. 
One of the most apparent physiologic roles that both S1P and LPA play is in 
vasculogenesis which was demonstrated by the various receptor knockout mouse lines 
described above.  The S1P1 receptor itself was first discovered because it was 
overexpressed under conditions where endothelial cells are induced to form capillary-
like structures in vitro76.  Likewise, deletion of the S1P1 receptor specifically in 
endothelial cells results in vascular development problems comparable to global 
knockout of the gene106.  The role of S1P in endothelial cells in particular has thus been 
studied extensively.      Aside from the role it plays in vascular development during 
embryogenesis, S1P also plays a clear role in maintaining endothelial (and also 
epithelial) barrier function.  This has been observed in vitro where siRNA knockdown 
resulted in decreased electrical resistance of a monolayer of endothelial cells107 and in 
vivo where pharmacological antagonism of S1P1 resulted in pulmonary edema108.  The 
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effects of LPA on endothelial cells have been studied less than that of S1P.  LPA does 
appear to have an effect on endothelial barrier function but there are inconsistencies in 
the literature regarding whether LPA increases109, 110 or decreases111, 112 barrier function.  
Outside of its role in barrier function, LPA plays an inflammatory role by upregulating 
several adhesion receptors113 and chemokines114 in endothelial cells.  Recently, LPA has 
been shown to actually promote athergenosis in Apoe-/- mice presumably by inducing 
chemokine release from endothelial cells and subsequent adhesion of monocytes115. 
A further function of both S1P and LPA in endothelial cell function is that both are 
capable of inducing endothelial nitric oxide synthetase (eNOS) which implicates a role 
for these lipids in regulating vascular tone116, 117.  Although the responses can be 
complex, a change in mean arterial blood pressure is observed when either S1P or LPA is 
administered globally in different animal models69, 118.  In addition to modulating 
vascular tone via eNOS induction, smooth muscle cells themselves express receptors for 
both LPA and S1P119-122.  Local administration of LPA or S1P in certain arteries (or in 
cultured myocytes from certain arteries) induces contraction indicating these 
lysophospholipids are capable of directly affecting vascular smooth muscle function121-
123.  Aside from simply causing contraction of smooth muscle cells, S1P and LPA are able 
to phenotypically alter smooth muscle cells, enhancing their proliferative and migratory 
propensity which can ultimately lead to neointima formation and vascular remodeling89, 
120. 
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Aside from the role that platelets play in producing LPA (see “Lysophospholipid 
Distribution and Metabolism” above), LPA also plays a role in platelet signaling and 
activation.  LPA is a weak activator of platelets isolated from most human donors, 
although rodent platelets are refractory to stimulation by LPA.  In human platelets, LPA 
stimulates platelet shape change124, 125, fibronectin matrix assembly126, and platelet-
monocyte coaggregate formation127.  LPA also synergistically enhances the actions of 
other platelets agonists, such as ADP and epinephrine128, 129.  S1P may also be a weak 
activator of platelets although compared with LPA it is not nearly as potent requiring 
high concentrations (> 10 µM) to induce platelet aggregation130.  This has led to 
speculation that a contaminant in S1P preparations or an S1P-derived metabolite may 
account for biologic activity towards platelets131.  Likewise, variable effects of LPC on 
platelets have been reported.  An early publication found that exposure of platelets to 
high dose LPC (30-100 µM) initially inhibited agonist-induced activation, but over time 
(30-90 minutes) could potentiate activation132.  This latter observation of time-
dependent activation of platelets by LPC suggests that activation may actually be due to 
LPA following lysoPLD-dependent metabolism of LPC.  More on the role of LPA in 
platelets will be discussed in Chapter 3. 
OVERVIEW 
Lysophospholipids are clearly poised to play a significant role in cardiovascular health 
and disease.  LPA and/or S1P may be involved in numerous roles in atherosclerosis as 
indicated by their abundant presence in lipoproteins and atheromas; their production 
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and metabolism by platelets and other blood cells; and their ability modulate the 
function of endothelial cells, smooth muscle cells, and platelets.  They may indeed have 
a role in every stage of atherothrombosis from fatty streak formation to plaque rupture 
and thrombosis.  To that end, the work presented herein is to delineate the role that 
platelets play in LPA production (Chapter 2) and to describe the mechanisms by which 
LPA signals in platelets (Chapter 3). 
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TABLE 1.1 
Receptor  Knockout Phenotype G proteins 
S1P1 Embryonic Lethal (deficient vascular maturation, 
hemorrhaging)  
Gi/o 
S1P2 Hearing/balance defects Gi/o; Gs;  Gq; G12/13 
S1P3 Grossly normal (infertility when deleted in 
conjunction with S1P2) 
Gi/o; Gq; G12/13 
S1P4 No knockout reported Gs; Gq; G12/13 
S1P5 Natural killer cell trafficking deficiency86 Gs; Gq; G12/13 
LPA1 50% perinatal death and wide developmental 
effects; notably CNS defects among other 
deficiencies 
Gi/o; Gq; G12/13 
LPA2 Grossly normal Gi/o; Gq; G12/13 
LPA3 Male infertility; Embryo implantation delay Gi/o; Gq 
LPA4 Grossly normal* Gs; G12/13; Gq, Gi 
LPA5 No knockout reported G12/13; Gq 
LPA6 No knockout reported G12/13; Gi 
 
Lysophosphlipid receptors:  Listed are brief overviews of the currently recognized LPA 
and S1P receptors, their association G proteins, and general phenotypes of knockout 
animals (reviewed in Chun et al, 2010133) 
*A separate group independently created a knockout of LPA4 and found the 
homozygous deletion to be embryonically lethal due to vascular deficiencies  and 
hemorrhaging103. 
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FIGURE 1.1 
 
Lysophosphlipid Structure: Lysophospholipids consist of a sphingoid or glycerol 
backbone (highlighted in red) with a single radyl group (highlighted in blue) and a 
phosphate group (highlighted in orange) with or without an additional group such as 
choline (highlighted green).  (A) S1P.  (B) LPA.  (C)  LPC.  
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FIGURE 1.2 
 
Schematic of Lysophospholipid Metabolism.  Lysophospholipids are generated from 
phospholipids, typically PC, by removal of a fatty acyl by an enzyme with PLA activity by 
transfer of a fatty acyl to cholesterol by LCAT during cholesterol esterification.  Serum 
phospholipids and lysophospholipids are generally associated with lipoprotein particles 
and are components of cellular membranes.  Removal of a headgroup from a 
lysophospholipid (most typically choline from LPC) by ATX yields the bioactive LPA.  
Circulating LPA is quickly degraded to MAG by a serious of LPPs.   
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FIGURE 1.3 
 
 
Phylogenetic Analysis of Human Lysophospholipid Receptors.  The evolutionary history 
was inferred by using the Maximum Likelihood method based on the JTT matrix-based 
model134. The tree with the highest log likelihood (-7814.8060) is shown. Initial tree(s) 
for the heuristic search were obtained automatically as follows. When the number of 
common sites was < 100 or less than one fourth of the total number of sites, the 
maximum parsimony method was used; otherwise BIONJ method with MCL distance 
matrix was used. The tree is drawn to scale, with branch lengths measured in the 
number of substitutions per site. The analysis involved 13 amino acid sequences. All 
positions containing gaps and missing data were eliminated. There were a total of 289 
positions in the final dataset. Evolutionary analyses were conducted in MEGA5135.  On 
the left are the EDG Family of receptors while on the right are non-EDG family 
receptors.  The ADP receptors P2Y12 and P2Y1 are shown for comparative purposes as 
LPA4 and LPA6 were originally classified as P2Y receptors. 
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CHAPTER 2:  PLATELET INTEGRINS BIND ATX AND LOCALIZE ITS ACTIVITY 
Portions of this chapter are taken, modified, and expanded upon from Fulkerson et al, 
2011136. 
INTRODUCTION 
Evidence from transgenic animals49 and pharmacologic intervention52 reveal the critical 
role of ATX in the production of circulating LPA, a finding that has only recently become 
appreciated.  Circulating ATX levels and LPA levels correlate in human subjects as 
well137.  The source of extracellular LPA has not always been clear.  Intracellular LPA, 
which serves as an important mediator in triacylglyceride (TAG) production in most 
cells138, may be produced by different mechanisms58.  An unknown circulating lysoPLD 
was first suggested by Tokumura et al in 1986 by simple comparison of relative 
phospholipid species in the plasma139.  ATX itself was later identified as a glycoprotein 
secreted from a line of human melanoma cells, inducing motility in an autocrine 
fashion140 (hence its most common designation). 
The first recognition of the enzymatic activity of ATX came when it was found to possess 
significant homology with an extracellular nucleotide pyrophosphatase, ENPP1141 (ATX 
was subsequently given the additional designation, ENPP2).  Of the ENPP family, ENPP1-
3 have the greatest sequence homology.  They all possess a modular structure with two 
amino- (N) terminal somatomedin domains (SMB1,2) followed by a phosphodiesterase 
domain (PDE) and finally a carboxy- (C) terminal nuclease-like domain (NUC)142 (Figure 
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2.1A).  Unlike ENPP1 and ENPP3, which are integral membrane proteins, ATX is a 
secreted enzyme142.  While each of these possess activity against substrates such as 
nucleotides and other various phosphodiesters, ATX is unique in that it was found to 
also possess lysoPLD activity143 and was indeed identified as the circulating lysoPLD 
found in plasma144.  ATX itself actually has relatively poor ENPP activity compared with 
ENPP1 and ENPP3145.  Although the substrates of the ENPP1-3 enzymes vary widely, the 
catalytic activity of each enzyme requires a critical threonine in the catalytic site of the 
PDE domain143.  The actual structural determinants that account for each enzyme’s 
diverse substrate preferences initially remained enigmatic.  While the catalytic 
determinants are within the PDE domain, domain swapping experiments between 
ENPP1 and ATX have demonstrated that all three domains of ATX are necessary for 
lysoPLD activity. 
Recently two groups have independently reported a crystal structure for ATX providing 
insights into the lysoPLD-specifying determinants (Figure 2.1B)146, 147.  Extensive 
interactions exist between the PDE and NUC domains and weaker interactions between 
the two SMB domains and the PDE domain.  An extended hydrophobic substrate binding 
channel leading to the active site is formed in large part by the interface between the 
SMB and PDE domains. This channel appears to have arisen by deletion of sequences 
that are present in other ENPP proteins. LysoPLD activity can be ablated while the ENPP 
activity remains unhindered by the introduction of mutations of hydrophobic residues 
that line the channel145-147.  The pocket itself is large enough for a single acyl group 
explaining why ATX may use lysophospholipids as substrates but not phospholipids with 
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two acyl groups146.  Taken together these observations account for the unique 
selectivity of ATX for lysophospholipid versus small molecule substrates. 
With the evident role of ATX and LPA in human physiology and disease (see Chapter 1), 
there has developed an impetus for developing specific pharmacologic inhibitors to ATX.  
Early observations on the regulation of ATX indicated that both LPA and S1P were 
capable of inhibiting ATX activity148.  This led to the identification of a number lipid-
based ATX inhibitors149-151 including the newly FDA-approved immunomodulator FTY720 
(fingolimod) phosphate152.  More recently non-lipid boronic acid-based inhibitors (eg, 
HA155) have been developed with nanomolar potency which globally inhibit ATX 
activity when they are administered in the blood52, 153.   Molecules such as HA155 
possess hydrophobic ring systems which allow them access to the hydrophobic pocket 
of ATX via van der Waals interactions146.  This structure gives these particular inhibitors 
specificity to ATX compared with other ENPPs. 
As described in Chapter 1, a role for platelets in production of circulating LPA has been 
suggested.  While platelets themselves are clearly not a major source of ATX in the 
plasma, these observations raise the possibility that activated platelets or perhaps 
microparticles formed by activated platelets are a source of LPC substrate for ATX. 
Recent work identified acyl-protein thioesterase 1 (APT1) as being released during 
thrombin-activation of platelets and essential for platelet LPA production55. The PLA1 
activity of APT1 generates sn-2 LPC on the outer surface of the membrane bilayer, which 
is proposed to undergo acyl migration to sn-1 LPC and serve as a substrate for ATX55. 
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This process would necessitate that ATX localizes to the platelet surface.  However, the 
mechanisms involved in cell localization of ATX and their importance for ATX-catalyzed 
production of LPA are presently unclear. 
Unlike ENPP1 and ENPP3, ATX is a secreted protein although there have been 
suggestions that ATX may be able to accumulate at the surface of cells.  One report 
demonstrates that ATX binds to and is cleared by liver sinusoidal scavenger receptors154.  
The modular structure of ATX itself suggests interaction with integral adhesive 
receptors.  Its SMB domains display a degree of homology to the SMB domain of 
vitronectin, a protein capable of interaction with both plasma proteins and integrins via 
high-affinity interactions with its SMB domain155-159.  To that end, evidence for binding 
of ATX to additional integrin receptors on lymphocytes160 and oligodendrocytes161 has 
been presented.  Furthermore the presence of ATX has been shown in arterial thrombi 
of wild type mice but not mice lacking β3 integrins49.  Integrin activation could therefore 
serve as a mechanism to localize the recruitment of ATX and spatially and temporally 
regulate LPA production.  Not only would this provide a novel mechanism for localizing 
LPA signaling, but it would also provide a novel way for LPA production to be blocked 
under very specific circumstances. 
In the following account, the integrin selectivity of ATX binding to platelets and 
mammalian cells was investigated as was the regulation of this process by cell signaling 
pathways. Using antibody and small molecule inhibitors of the ATX-integrin interaction 
and newly developed ATX mutants with impaired integrin binding it is demonstrated 
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that recruitment of ATX to the surface of platelets and mammalian cells is a mechanism 
for localized LPA production. 
METHODS 
Mice 
All procedures conformed to the recommendations of the "Guide for the Care and Use 
of Laboratory Animals" (Department of Health, Education, and Welfare publication 
number NIH 78-23, 1996), and were approved by the Institutional Animal Care and Use 
Committee. β3-deficient (Itgβ3−/−) were a generous gift from Barry Coller (Rockefeller 
University).  They were initially produced by deletion of exons 1 and 2 on the itgb3 gene 
as described by Hodivala-Dilke et al162.  The mice were weaned at 21 days, maintained 
on a 12-h light and 12-h dark cycle, and fed water and standard rodent chow (2018 
Harlan Tekland Rodent Diet) ad libitum. 
Blood Collection 
Blood was collected from healthy donors with approval from the Institutional Review 
Board at the University of Kentucky by cubital venipuncture with a 19 gauge needle and 
collected into citrate (final citrate concentration 0.38%). For studies of isolated murine 
platelets, we collect blood by retrooribital puncture performed under anesthesia as 
previously described163.  Citrated whole mouse blood (500 µl) was mixed with an equal 
volume of a solution of citrated saline buffer (0.38% citrate, 150 mM NaCl) and 
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centrifuged (300g for3 min) at room temperature to obtain a platelet-and plasma-rich 
buffer fraction. 
Isolation of Recombinant ATX  
cDNAs encoding wild type ATX, catalytically inactive ATX-T210A an N-terminal ATX 
fragments containing amino acids 53-143 and various site directed mutants were 
generated using standard methods inserted into a variant of pSecTag (Invitrogen) that 
was engineered for compatibility with the Gateway cloning system. Proteins were 
expressed by liposome mediated transfection of these constructs in suspension cultures 
of CHO cells. Recombinant proteins were purified from filtration concentrated CHO cell 
culture medium by nickel chelation chromatography as described previously49.  
Particular ATX truncations (SMB1-2) and ATX point mutations were engineered by Tao 
Wu, PhD (Figure 2.2B and Figure 2.3B respectively).  Dr. Wu and the author additionally 
characterized the lysoPLD activity of the mutants using BSA-associated substrate (Figure 
2.3C) and bis-paranitrophenotoluene (see “Measurement of LPA Production” for 
details). 
Preparation of Platelets 
Citrated human blood was centrifuged at 450 x g for 5 minutes to yield platelet rich 
plasma (PRP), to which 134 nM prostaglandin I2 (PGI2) was added. Platelets were 
separated from plasma by filtration of PRP using a column of Sepharose 2B (Sigma) 
equilibrated in HEPES-buffered modified Tyrode’s buffer (138 mM NaCl, 5.6 mM 
dextrose, 2.7 mM KCl, 10 mM HEPES, 12 mM NaHCO3, 0.36 mM NaH2PO4, pH 7.35) with 
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0.35% fatty acid-free bovine serum albumin (BSA; US Biological).  For adhesion assays, 
PRP was incubated with 7 μM calcein AM for 30 minutes at 37°C prior to gel-filtration. 
Unless otherwise indicated, gel-filtered platelets  were diluted to 200,000/μl in Tyrode’s 
containing fatty acid free (ethanol and charcoal extracted) BSA (Sigma Aldrich). 
Static Platelet/Cell Adhesion Assay 
Recombinant wild type ATX, ATX variants, or fibrinogen (American Diagnostica) diluted 
in Tris buffer (50 mM Tris, 100 mM NaCl, pH 7.4) was incubated in wells of a black 
polystyrene 96 well plate (Nunc) overnight at 4°C. The wells were subsequently 
incubated for 1 hour at room temperature with Tyrode’s containing BSA to block non-
specific binding sites. Calcein-labeled platelets or CHO cells (see below) were incubated 
for 1 hour at 37°C; non-adherent platelets were removed by washing Tyrode’s 
containing BSA and 2 mM Ca2+ and 1 mM Mg2+, or Mn2+ , as indicated. The number of 
adherent platelets was determined by measuring fluorescence (abs/emi = 494/517 nm) 
and reference to a standard curve generated by fluorescence measurements using 
independently quantitated numbers of platelets. For analysis of platelet spreading and 
morphology, platelets were diluted to 20,000 /μl and adhesion performed on LabTek2 
coverslips. Adherent platelets were fixed with 4% paraformaldehyde, permeabilized, 
and stained with TRITC-phalloidin.  
Platelet Aggregation 
Isolated platelets were prepared by gel filtration into Tyrode’s with BSA as described 
above and diluted to 200,000 /µl.  2 mM Ca2+ and 1 mM Mg2+ was added as was 
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fibrinogen where indicated.  400 µl isolated platelets were aggregated using the 
indicated agonists at 37°C under stirring conditions.  Aggregation was measured by light 
transmission (Platelet-Ionized Calcium Aggregometer; Model 660; Chrono-log). 
Radioiodination of ATX 
ATX was radiolabeled using sodium iodide-125 (Na125I). 400-500 μg ATX was incubated 
with a final concentration of 0.4 M glycine, 5-10 mCi Na125I per mg protein, and lastly 
23.1 nmol ICl / mg protein for 5 minutes on ice. 125I-ATX was dialyzed overnight at 4°C 
against phosphate-buffered saline (PBS). Ninety-five to 99% of the 125I associated with 
the ATX was precipitated by trichloroacetic acid. 125I-ATX was combined with platelets in 
the absence of presence of agonists and incubated at room temperature. Platelets were 
centrifuged at 16,000 x g for 30 s through 30% sucrose, and the amount of radioactivity 
associated with the platelet pellet determined (PerkinElmer, Packard Cobar II Auto-
Gamma).  
CHO Cells 
Chinese hamster ovary (CHO) cells stably expressing human β3 integrin were a generous 
gift from Zhenyu Li (University of Kentucky). For binding experiments these cells were 
labeled with calcein using minor modifications of the method described for platelets 
above. For measurements of LPA production by ATX, CHO cells were incubated with bee 
venom PLA2 (Sigma Chemical Co) at concentrations of 0-10 μg/ml for up to 60 minutes. 
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Determination of lysoPLD activity using detergent solubilized substrates. ATX activity 
against 18:0 LPC was determined using a spectrophotometric coupled enzymatic assay 
with minor adaptations for use in a microplate reader144.  
Measurement of LPA production 
The lysoPLD activity of ATX was measured in the absence and presence of platelets, 
stably-transfected CHO cells, and purified integrins. Lipids were extracted using acidified 
organic solvents as described previously. When measuring changes in endogenous 
lipids, the unnatural lipid C17 LPA was added as an internal standard. In cases where we 
measured production of C17 LPA by ATX catalyzed hydrolysis of C17 LPC, we substituted 
C17 S1P as the recovery standard. The organic phase from these extractions was 
recovered, evaporated to dryness and reconstituted in 100 μl methanol. Lipids 
(generally 10 μl of each sample) were separated by reverse phase HPLC on an Agilent 
Zorbax C8 column and quantified by tandem mass spectrometry using an ABI 4000 Q-
Trap hybrid linear ion trap triple quadrupole mass spectrometer. The mass 
spectrometer was operated in selective reaction monitoring mode to measure lipid 
species specific precursor product ion pairs with quantification accomplished by 
reference to calibration curves generated using synthetic standards obtained from 
Avanti Polar Lipids that were independently quantitated by phosphorous analysis as 
described previously52 . 
To measure real time production of ATX activity / LPA production in solution, we used 
fluorescent reporter systems to analyze choline liberation.  Various concentrations of 
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LPC solubilized with Triton-X 100 were incubated with 0.1 mM amplex red (Cayman 
Cehmical Co.), 2 U/ml horseradish peroxidase (Sigma) and 0.2 U/ml choline oxidase 
(Sigma) in a black microtiter plate.  Final buffer conditions were 50 mM Tris pH 8.0, 100 
mM NaCl, 5 mM MgCl2.  Incubations were conducted at 37°C for 1 hour and 
fluorescence measurements were made using an excitation wavelength of 540nm and 
measuring emission of 590 nm.  Choline calibration curves were used to evaluate 
kinetics in molar quantities. 
Statistics 
Statistical analyses and preparation of figures were conducted using SigmaStat and 
SigmaPlot, respectively.  Specific statistical tests are indicated in figure legends. 
RESULTS 
Synergistic Effect of Platelet Activation and ATX on LPA Generation 
The central role of ATX in the production of circulating, bioactive LPA has been 
established by a combination of genetic and pharmacologic approaches. Very little is 
known about physiological mechanisms that may be responsible for regulating LPA 
production by ATX.  Several observations suggest that platelets may serve as a useful 
model system to study regulation of ATX activity.  Isolated platelets produce LPA after 
agonist stimulation, in a process that appears to involve platelet release of APT1 and 
APT1-catalyzed generation of LPC, which presumably serves as a substrate for ATX55.  To 
confirm the role of ATX in platelet LPA generation, we tested the effects of a recently 
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described, potent, small molecule inhibitor of ATX52. We found that resting platelets 
contained significant levels of LPC, and these levels were increased ~2-fold after 
stimulation with maximally effective dose of thrombin (0.5 U/ml) for 30 minutes, 
presumably as a result of the recently described PLA1 activity of APT155. This dose of 
thrombin increased the LPA content of isolated platelets ~6-fold after 30 minutes. The 
thrombin-mediated increase in platelet-derived LPA was completely attenuated in a 
dose-dependent manner by the ATX inhibitor HA155 (Figure 2.4A). Platelets contain 
immunologically detectable ATX49, so these results indicate that ATX likely accounts for 
the previously reported ability of isolated human platelets to generate LPA in response 
to agonists58, 164.  Remarkably, thrombin-stimulated LPA generation by isolated platelets 
was dramatically increased when recombinant ATX was added to these incubations.  
The increase in LPA production was dependent on the concentration of added ATX with 
a half maximal effect observed at concentrations of ~100 nM (Figure 2.4B), which is in 
the range of the concentration of ATX reported in human plasma165. When incubated 
with a maximally effective concentration of ATX, LPA generation by platelets was 
sustained at times of at least 20 minutes (Figure 2.4C, D).  The time course of LPA in the 
absence of added ATX or in response to a maximally effective concentration of ATX in 
the absence of agonist was biphasic  (Figure 2.4C, D), which may reflect the previously 
reported ability of platelets to degrade LPA166.  The low concentration of delipidated 
BSA in these incubations contained trace levels of lysophospholipids including LPC that 
could not sustain the quantities of LPA being formed and indeed the production of LPA 
by ATX. Taken together, our observations of sustained, amplified LPA production by 
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thrombin-stimulated platelets in the presence of ATX indicates that under these 
conditions ATX is acting on platelet-generated LPC under conditions where the supply of 
substrate to the enzyme is not a rate-limiting determinant of LPA production. 
Signaling Pathways Regulating Binding of Platelet Integrins to ATX 
The ability of ATX to interact with integrin receptors could provide a mechanism for 
localizing the enzyme along the platelet surface. We therefore characterized ATX-
platelet integrin interactions in more detail. LPA is a weak platelet agonist. To avoid 
confounding effects of ATX-generated LPA, we used a catalytically inactive mutant ATX-
T210A to investigate agonist-dependent signaling pathways that regulate binding to 
platelets. To evaluate this interaction, we initially used a static adhesion method 
wherein purified recombinant ATX-T210A was immobilized followed by incubation of 
platelets (see Methods).  We found that resting platelets alone had no measurable 
adhesion to ATX-T210A, but platelets stimulated with 10 µM ADP adhered to ATX-T210A 
maximally when it was immobilized at 5-10 µg/ml (Figure 2.5A; originally published in 
Pamuklar et al49).  We further evaluated the effect of a number of platelets agonists.  
Agonists that act through GPCRs including ADP, PAR1 (thrombin and thrombin receptor 
activating peptide; TRAP) as well as agonists acting through the non-GPCR GPVI pathway 
(collagen), all promoted platelet adhesion to ATX-T210A (Figure 2.5B).  In keeping with 
known mechanisms of integrin activation, ADP-stimulated platelet adhesion to ATX was 
inhibited by pretreatment of platelets with forskolin, which elevates intraplatelet cAMP, 
and was partially reduced by inhibitors of protein kinase A (PKI 14-22), PI3-kinase 
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(LY294002) or Rho kinase (Y27632) (Figure 2.6A).  ADP-promoted platelet adhesion to 
ATX-T210A was also attenuated by the P2Y12 receptor antagonist cangrelor and the 
P2Y1 antagonist MRS-2719 (Figure 2.6B). Cangrelor and apyrase (an ADPase) also 
inhibited adhesion of TRAP-stimulated platelets to ATX (Figure 2.6B), identifying a role 
for released ADP in PAR1-stimulated platelet adhesion to ATX-T210A.  In addition to 
classic platelet agonists, the direct integrin activator Mn2+ and treatment of platelets 
with the reducing agent dithiothreitol (DTT), which stimulates the adhesive function of 
several integrins, resulted in agonist- independent adhesion to ATX (Figure 2.7). 
In agreement with the hypothesis that integrins mediate this interaction between 
activated platelets and immobilized ATX, we found that echistatin, an RGD-containing 
peptide that competitively inhibits ligand binding to β1 and β3 integrins, dose-
dependently reduced platelet adhesion to ATXT210A to levels observed in unstimulated 
platelets (Figure 2.8A). To evaluate the specific integrins involved in ATX-T210A 
interaction with platelets we used integrin function-blocking antibodies. Monoclonal 
antibodies to β3 integrins (7E3) reduced adhesion by 79 ± 6% (n = 8).  Monoclonal 
antibodies to integrin αIIbβ3 (10E5) and to β1 integrins (P4C10) also reduced adhesion 
of platelets to ATXT210A by 65 ± 13% (n = 4), and 87 ± 6% (n = 2), respectively (Figure 
2.8B). The specificity of P4C10 was confirmed by its lack of an effect on fibrinogen 
binding to platelets which mostly involves αIIbβ3.  LM609, a function blocking αVβ3 
antibody, had variable effects on the adhesion of platelets from three different donors 
to ATX-T210A, ranging from 1 to 62% inhibition (median inhibition 22%), which may 
reflect low and variable levels of platelet αVβ3 expression in platelets from different 
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donors.  Other integrin antibodies that have not previously been shown to affect binding 
of integrin ligands (12G10 and 23C6) had no effect on adhesion (Figure 2.8B).  Binding to 
ATX-T210A was substantially, but not completely, impaired in platelets from mice 
lacking β3 integrin (Itgβ3-/-). Murine platelet adhesion was inhibited by 1B5, a hamster 
monoclonal antibody to murine αIIbβ3 (Figure 2.9). Taken together, our results indicate 
that the association of ATX with platelets requires integrin activation and occurs through 
β3 and β1 integrins. 
To determine if β3 integrins were sufficient for supporting cell adhesion to ATX, we 
examined the effect of expressing the integrin β3 subunit alone or in combination with 
αIIb on CHO cell adhesion to ATX-T210A. While the parental CHO cell line did not adhere 
significantly to ATX-T210A, CHO cells expressing β3 integrins acquired the ability to 
interact with ATX-T210A in the presence of the integrin activator Mn2+ (Figure 2.10). The 
interaction of CHO cells with ATX-T210A was specifically mediated by β3 integrins 
because it was completely blocked by 7E3 (Figure 2.10). Because integrin β3 associates 
with the widely expressed vitronectin αV subunit of CHO cells (which do not express the 
platelet specific αIIb subunit), these observations also establish that ATX-T210A binds to 
αVβ3 indicating that association with this integrin may account for ATX binding to other 
cell types. 
The preceding observations of ATX binding to integrins on platelets and mammalian 
cells employed microtiter plate assays with immobilized ATX. We next investigated 
binding of soluble 125I-labeled ATX to platelets in suspension. Importantly, 125I-ATX 
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behaved identically to unlabeled ATX in both static adhesion assays and in activity 
assays (data not shown).  Binding of 125I-ATX to activated platelets was time-dependent 
and saturable (Figure 2.11A-C).  Scatchard analysis of data obtained using an excess of 
unlabeled ATX to define non-specific binding revealed an affinity of ~300 nM and a 
maximal number of ~75,000 ATX binding sites / platelet. Excess echistatin displaced 
bound 125I-ATX (Figure 2.11C) and unlabeled fibrinogen dose-dependently blocked 125I-
ATX binding to platelets with a Ki of 220 nM (Figure 2.11D). 
LysoPLD-Independent Effects of ATX on Platelet Aggregation and Adhesion 
We sought to evaluate possible impacts integrin binding had on platelet function 
indepenent of its lysoPLD activity which has been reported in oligodendrocytes167.  ATX 
is a monomeric protein in solution168 and would not be expected to support platelet 
aggregation, which requires cross-linking of at least 2 binding sites on adjacent platelets. 
Under conditions where ADP-induced aggregation of washed platelets was enhanced by 
addition of exogenous fibrinogen, inclusion of soluble ATX-T210A did not further 
enhance platelet aggregation (Figure 2.12A).  In fact, the maximal extent of aggregation 
of platelets was moderately lower in the presence of ATX-T210A (Figure 2.12A and 
Figure 2.12B) even after addition of exogenous fibrinogen (Figure 2.12B). The ability of 
ATX-T210A to reduce platelet aggregation varied between platelet preparations from 
different donors (Figure 2.12B right), but the extent of aggregation observed 
consistently lower in the presence of ATX-T210A. Taken together, these observations 
and the fact that fibrinogen competes for soluble ATX binding (Figure 2.11D) are 
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consistent with a model in which ATX and fibrinogen interact with a mutually accessible 
binding site(s) on platelets but only fibrinogen can support platelet aggregation. 
ATX exerts a counter-adhesive effect on oligodendrocytes that is consistent with 
inhibition of integrin-dependent adhesion and signaling161.  ATX may also be capable of 
hydrolyzing nucleotides along the platelet surface that could impact signaling events. 
The inhibitory effects of ATX on platelet aggregation were independent of catalytic 
activity because inactive ATX-T210A also inhibited aggregation (Figure 2.12).  
Nonetheless, we sought to determine if ATX has direct inhibitory effects on platelet 
function by determining of ATX would alter adhesion to fibrinogen immobilized at 
submaximal concentrations (low density; 1 μg/ml). In the absence of agonists, platelets 
adhere to low-density fibrinogen and the adhesion triggers platelet activation169, 170.  In 
agreement with our aggregation studies, soluble ATX blocked platelet adhesion to 
immobilized fibrinogen by 70% (from 9.6 ± 2.0 to 2.8 ± platelets/ high powered field). 
However, more platelets adhered to surfaces containing both immobilized fibrinogen 
and ATX than to surfaces containing fibrinogen alone (20 ± 5 versus 9.6 ± 2 
platelets/field; Figure 2.13A, B). In addition, more platelets spread on surfaces with 
immobilized fibrinogen and ATX than spread on surfaces containing immobilized 
fibrinogen alone (Figure 2.13A, B).  When fibrinogen was immobilized at higher density 
concentrations (5 μg/ml) that are known to promote maximal platelet activation and 
adhesion169, 170, the inclusion of immobilized ATX did not inhibit adhesion or spreading 
(Figure 2.13A, B). Thus, rather than negatively affecting the adhesive function of platelet 
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integrins, as has been observed in experiments with oligodendrocytes, immobilized ATX 
moderately facilitates platelet adhesion to fibrinogen. 
The Tandem SMB Domains are the Sole ATX Binding site for β3 Integrins 
We next sought to identify the motifs in ATX responsible for interacting with platelets. 
ATX contains an arginine-glycine-aspartic acid (RGD) sequence motif within the second 
SMB-like domain (Figure 2.2A). Because this motif confers integrin binding to other 
proteins, including the structurally related SMB-like domain of vitronectin, we surmised 
that it would perform a similar function in ATX. Surprisingly, the ATX crystal structure 
(Figure 2.1B) revealed that the RGD motif amino acids are incompletely solvent exposed 
(Figure 2.3A). In agreement, we found that non-conservative substitutions of the RGD 
residues did not abolish integrin binding (Morris, unpublished observations). However, 
in the course of these studies, we found that mutation of a charged, surface-exposed 
residue at the N-terminus of the ATX SMB2 domain significantly reduced binding of ATX 
to platelet integrins identifying an important role for the SMB2 domain in this 
process146.  To determine if the SMB2 domain is the sole integrin binding site on ATX 
and begin to explore interactions of ATX with integrins on other cells, we compared 
binding of an ATX fragment containing the tandem SMB domains to CHO cells 
expressing human integrin β3. Binding of these cells to the SMB domain fragment was 
promoted by the integrin activator Mn2+ and inhibited by 7E3 in an identical manner to 
that of WT ATX, indicating that the SMB domains (and not the PDE and NUC domains) 
account for ATX binding to β3 integrins (Figure 2.14A, B). 
  
 
41 
ATX Binding to Platelet Integrins Enables Agonist Stimulated LPA Production 
Having established the properties of ATX binding to β3 integrins, we used platelets and 
CHO cell systems to test the hypothesis that integrin-mediated recruitment of ATX to 
the outer face of the plasma membrane enables localized LPA production.  To 
investigate this possibility, we measured the rate of hydrolysis of BSA bound C17-LPC 
(an unnatural LPA species) in the presence of either the parental CHO cell line or αIIIbβ3 
expressing CHO cells using Mn2+ as the integrin activator.  Under conditions where, 
based on our measurements of the affinity of platelet αIIbβ3 for ATX, all of the added 
ATX would be bound to the integrin, we observed a ~2-fold increase in ATX activity in 
the presence of integrin-expressing cells (Figure 2.15A). These results indicate that 
integrin binding increases ATX activity against exogenous substrates. Our experiments 
with activated platelets indicated that integrin-bound ATX could act on endogenously 
generated lysophospholipid substrates. Although like resting platelets, parental and 
αIIbβ3 expressing CHO cells contained readily detectable LPC, we did not observe 
significant production of LPA when they were incubated with ATX.  However, we found 
that preincubation of these cells with bee venom PLA2 increased cell-associated LPC 
levels (Figure 2.15B), which presumably reflects the ability of this enzyme to hydrolyze 
PC in the outer leaflet of the plasma membrane when added exogenously to 
mammalian cells. Under these conditions, ATX elicited concentration-dependent 
increases in cell-associated LPA, and, at lower concentrations of ATX, LPA production 
was increased ~4-fold by overexpression of αIIbβ3 (Figure 2.15C). The effect of ATX was 
substantially attenuated when the integrin blocking antibody 7E3 was included in these 
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incubations (Figure 2.15D). Because the parental CHO cell line failed to bind to ATX 
appreciably in the static adhesion assay (Figure 2.10), it is likely that relatively low levels 
of integrin binding are sufficient to sustain significant production of LPA by cell-
associated ATX. 
The crystal structures reported are of rodent ATX orthologs (Figure 2.1)146, 147.  Tao Wu , 
a postdoctoral fellow in our laboratory, made variants of human ATX with 
nonconservative substations of charged surface exposed residues in the SMB2 domain 
including H117A which corresponds to H119A of the rodent sequence and was 
previously shown to exhibit decreased binding to platelet β3 integrins146 (Figure 2.2A 
and also see Figure 2.3B for sequence details). He examined catalytic activity of these 
variants against mixed micelles of triton X-100 and 18:0 LPC as described in the 
introductory section of this chapter. The apparent Km and Vmax values for LPC of these 
SMB domain mutants were very similar to that of wild type ATX indicating that mutation 
of the SMB2 domain does not impair catalytic activity against detergent-solubilized 
substrates (Figure 2.3C). Activity of these variants against the small molecule substrate 
bis-paranitrophenol phosphate was also indistinguishable from wild type ATX (data not 
shown). We examined binding of these ATX SMB2 domain variants to β3 integrin 
expressing CHO cells. Binding of these cells to ATX-H117A and ATX-E109A but not ATX-
R117A was significantly lower than to wild type ATX (Figure 2.16A). We then compared 
the ability of WT ATX and ATX-E109A to increase LPA production when incubated with 
thrombin stimulated platelets. While WT ATX produced a robust increase in LPA 
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production ATX E109A did not, indicating that association with β3 integrins is important 
for this process (Figure 2.16B). 
DISCUSSION 
LPA is produced and degraded by multiple pathways and also serves as an intermediate 
in the de novo synthesis of phospholipids. Here a mechanism is described by which the 
metabolic and signaling functions of LPA can be delimited by localizing LPA production 
to the cell surface through recruitment to activated integrin receptors. We used human 
platelets as a model system to dissect the regulation and specificity of integrin binding 
to ATX. We found that a disparate variety of platelet agonists promote ATX binding to 
platelets. The ability of agonists to stimulate ATX binding appears to be strongly 
dependent on ADP signaling through the P2Y12 purinergic receptor, as evidenced by the 
ability of cangrelor and apyrase to inhibit TRAP-induced adhesion to immobilized ATX.  
The finding that forskolin treatment abolishes platelet adhesion to ATX is also consistent 
with a role for P2Y12 signaling through Gi to decrease platelet cAMP levels as an 
important component of the signaling pathway responsible.  Stimulation of platelet 
adhesion to ATX by Mn2+ in the absence of agonists implicates integrins in this process, 
and studies using integrin blocking antibodies and CHO cells expressing recombinant 
integrins indicate a role for β3 integrins (αIIbβ3 and αVβ3) and to a lesser extent β1 
integrins in this process. The involvement of integrins in platelet binding to ATX is 
consistent with the density of ATX binding sites/platelet observed with radiolabeled 
soluble ATX binding experiments. These results raise the possibility that, because αVβ3 
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and β1 integrins are broadly expressed, cell surface recruitment of ATX through integrin 
binding may be a widespread phenomenon. 
Consistent with this idea, binding of ATX to lymphocytes and oligodendrocytes has been 
reported previously160, 161.  In the latter system ATX binding was shown to disrupt cell 
adhesion through a process that was postulated to involve antagonism of an 
unidentified adhesive receptor161. We found that ATX impedes fibrinogen-dependent 
platelet aggregation. This is likely because ATX and fibrinogen compete for binding to 
the same integrin receptors but as ATX is a monovalent integrin ligand it cannot support 
platelet aggregation.  Consistent with this idea, we found that fibrinogen competitively 
inhibited binding of soluble radiolabeled ATX to platelets. However, when ATX and 
fibrinogen were immobilized together at submaximal concentrations, we found that ATX 
modestly enhanced, rather than inhibited, adhesion. Thus, unlike ATX binding to 
oligodendrocytes which appears to trigger signals that inhibit other adhesive events, our 
results are consistent with a model in which fibrinogen and ATX compete for the same 
binding sites on platelets. Our prior observation that ATX is recruited to a thrombus in 
vivo suggests that the interaction of ATX with activated platelet integrins we have 
characterized here in vitro occurs physiologically49. In in vitro assays, ATX displays ENPP 
activity. It is possible that localization of ATX along the platelet surface provides a 
mechanism for degradation of released ATP (a platelet inhibitor) and ADP (a platelet 
activator). To date, however, we have been unable to detect an impact of ATX on 
circulating nucleotides171. 
  
 
45 
Efforts to define the physiological role of LPA signaling in platelet function have been 
confounded by observations of heterogeneity in human platelet responses to LPA172 and 
the fact that, while LPA is a weak agonist for human platelets from most donors, it does 
not activate rodent platelets49.  On the other hand, several lines of evidence implicate 
platelets as important participants in the production of LPA in whole blood ex vivo and 
in mouse models58, 61. We found that a recently described potent small molecule ATX 
inhibitor completely attenuated production of LPA by thrombin stimulated washed 
platelets. The delipidated BSA used in these incubations contained trace levels of LPC 
that were less than 1% of the quantity of LPA being generated, so clearly these results 
indicate that endogenous ATX acting on endogenously formed LPC is responsible for 
producing LPA in this system. Addition of purified ATX to washed platelets at 
concentrations in the range of ~100 nM, which are in line with those present in plasma, 
resulted in dramatically enhanced sustained production of LPA by thrombin stimulated 
washed platelets. We also found that ATX could hydrolyze CHO cell-associated 
lysophospholipids and that this activity was substantially enhanced when cells 
expressing integrin β3 were used as the source of substrate.  We identified the N-
terminal ATX tandem SMB domain as sole site of integrin binding, and generated point 
mutants in the SMB1 domain of ATX that exhibited parallel reductions in binding to β3 
integrins and ability to generate LPA when incubated with thrombin stimulated 
platelets. Taken together, these results indicate that integrin binding to ATX brings the 
enzyme into close proximity with cell surface substrates which would generate LPA in 
the vicinity of its receptors (Figure 2.17).  Intriguingly, the ATX hydrophobic substrate 
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binding channel through which cell surface substrates and products must enter and 
leave the active site is formed from the interface between the SMB and PDE domains146, 
147 raising the possibility that integrin binding alters catalytic activity of the enzyme. 
While ATX can clearly generate LPA in blood plasma through hydrolysis of high 
concentrations of circulating LPC and this activity is important for maintaining plasma 
LPA levels in the ~1 μM range in the face of rapid elimination52, 173, very little is known 
about the extracellular concentration of LPA in tissues. Furthermore, although a role for 
circulating levels of the structurally related lipid mediator S1P in control of the 
permeability of lymphatic and vascular endothelium is well supported by substantial 
data, the function of plasma LPA remains enigmatic174. Our results suggest that the 
functions of circulating and cell-associated ATX are distinct. Recruitment of circulating 
ATX to activated platelets or the surface of vascular endothelial and vascular smooth 
muscle cells could lead to cell specific LPA generation and LPA signaling with important 
roles in vascular inflammation and injury responses174. 
Inhibition of LPA/ATX signaling is an attractive therapeutic target in cardiovascular 
disease, inflammation, and cancer. To date, all of the inhibitors of ATX activity 
described, including several recently reported highly potent compounds target the 
catalytic site of the enzyme to inhibit substrate binding or catalysis52, 175. The ATX-
integrin interaction reported here could be exploited to generate agents that selectively 
target ATX activity against cell-associated substrates. Indeed, antibody and small 
molecule inhibitors of integrin ligand interactions have already been developed as anti-
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thrombotic and anti-cancer agents and one compound of this type has been reported to 
alter LPA signaling involved in breast cancer metastasis in a mouse model61.  The 
possibility that some of the efficacy of these agents derives from inhibition of ATX 
recruitment to integrins warrants further examination. 
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FIGURE 2.1 
A 
 
B 
 
ATX Structure: (A) Schematic linear representation of ATX demonstrating the 
multimodular nature of the protein with the SMB1 domain in light magenta, the SMB2 
domain in dark magenta, the phosphodiesterase domain in green, the lasso region in 
orange and the nuclease-like domain in blue.  (B) Ribbon representation based upon x-
ray diffraction by the crystallized ATX.  As in A,  the SMB1 domain is in light magenta, 
the SMB2 domain in dark magenta, the phosphodiesterase domain in green, the lasso 
region in orange and the nuclease-like domain in blue.  Cysteine residues and disulfides 
are depicted in yellow.  The active site is indicated by the arrow with bound zinc ions 
(red) and phosphate (orange).  The critical threonine residue is black. 
 
Figure modified from Hausman et al146. 
  
SMB1 SMB2  Phosphodiesterase Nuclease Lasso 
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FIGURE 2.2 
 
 
Production of SMB1-2 peptide:  (A) Sequence alignment of the SMB1 and SMB2 
domains of human, rat and mouse ENPP2 (ATX) and human ENPP1 and ENPP3 with the 
RGD sequence underlined and charged residues targeted for mutation highlighted in 
red. (B) Analysis of purified recombinant wild type ATX (wtATX) and the N-terminal 
tandem SMB domain fragment(SMB1-2) by SDS PAGE and staining with coomassie blue. 
 
(B) Truncation generated by Wu136. 
 
  
A                                             SMB1                                                            SMB2 
hENPP2     CRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECP 
mENPP2     CRCDNLCKSYSSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLSRGDCCTNYQVVCKGESHWVDDDCEEIRVPECP 
rENPP2     CRCDNLCKSYSSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLSRGDCCTNYQVVCKGESHWVDDDCEEIKVPECP 
hENPP1     CRCDAACVELGNCCLDYQETCIEPEHIWTCNKFRCGEKRLTRSLCACSDDCKDKGDCCINYSSVCQGEKSWVEEPCESINEPQCP 
hENPP3     CRCDVACKDRGDCCWDFEDTCVESTRIWMCNKFRCGETRLEASLCSCSDDCLQRKDCCADYKSVCQGETSWLEENCDTAQQSQCP 
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FIGURE 2.3 
 
 
 
 
Preparation of SMB point mutations:  (A) Ribbon diagram of the SMB1-2 domains of 
ATX (purple) with the surface-exposed charged residues that were targeted for mutation 
in SMB2 highlighted in yellow (E109), orange (R111), and red (H117).  The partially 
exposed RGD sequence is in black. (B) SDS PAGE analysis of purified wild type ATX and 
the indicated variants. (C)  LysoPLD of ATX mutants using BSA-associated C17-LPC 
substrate. 
 
(A) Modified from Hausman et al146. 
(B) Mutants generated by Wu136. 
  
B 
A 
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FIGURE 2.4 
 
Synthesis of LPA by thrombin stimulated platelets is ATX-dependent and enhanced by 
exogenous ATX.  (A)  Gel-filtered platelets were treated with vehicle () or 0.5 U/ml 
thrombin  () in the presence of the indicated concentrations of  the ATX inhibitor 
HA155 for 30 minutes  and LPA quantitated as described in the materials and methods.  
(B)  LPA production by gel filtered platelets was determined in the presence of vehicle 
() or 0.5 U/ml thrombin () in the presence of the indicated concentrations of 
purified ATX and LPA quantitated as described in the materials and methods (C, D)  LPA 
production by gel filtered platelets was determined at the indicated times in incubations 
containing no added ATX and vehicle () or 0.5 U/ml thrombin () or 100 nM ATX and 
vechile () or 0.5 U/ml thrombin ().  Data shown are means of duplicate 
determinations (A, C, D) or mean ± SEM of triplicate determinations (B) from 
representative experiments that have been repeated using mulitple independent 
preparations of platelets. 
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FIGURE 2.5 
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Activated platelets adhere to ATX:  Gel-filtered, calcein-labeled platelets (200,000/μl in 
Tyrode’s buffer with 2 mM CaCl2 and 1 mM MgCl2 ) were incubated in microtiter wells 
containing ATX.  (A) Adhesion of resting platelets (closed circles) and platelets activated 
with 10 μM ADP (open circles) to ATX (immobilized at the indicated concentrations) and 
fibrinogen (immobilized at 10 μg/ml) for 1 hour at 37°C.  (B) Adhesion of platelets to 
ATX (immobilized at 5 μg/ml) in the absence of agonist (open bar) or in the presence of 
10 μM ADP, 15 μM thrombin receptor activating peptide (TRAP), 0.5 U/ml thrombin, or 
10 μg/ml collagen for 1 hour at 37°C. 
 
(A) Modified from Pamuklar et al49. 
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FIGURE 2.6 
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Platelet inhibitors block binding to ATX: (A) Platelets were incubated in wells with 
immobilized ATX in the absence of agonist or presence of TRAP and with either 100 μM 
forskolin, 20 μM LY294002 (PI3-kinase inhibitor) or 2.5 μM Y27632 (Rho kinase 
inhibitor). (*P<0.05 versus vehicle, ANOVA). (B) Where indicated, 0.5 μM cangrelor 
(P2Y12 antagonist), 10 μM MRS-2179 (P2Y1 antagonist), or 1 U/ml apyrase (ADPase) 
was included in the assay. (*P<0.05 versus ADP/vehicle, ANOVA; **P<0.05 versus 
TRAP/vehicle, ANOVA). 
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FIGURE 2.7 
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Mn2+ induces adhesion of resting platelets:  Platelets (in Tyrode’s buffer with the 
indicated divalent cations) were incubated in microtiter wells containing ATX 
(immobilized at 5 μg/ml) with vehicle (no agonist), 15 μM TRAP, 2.5 μM DTT, or 50 μM 
Mn2+. 
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FIGURE 2.8 
Echistatin (g/l)
0 5 10 15 20
A
d
h
e
re
n
t 
P
la
te
le
ts
 (
x1
0
0
0
)
0
200
400
600
800
1000
ADP
Unstimulated
A
 
No
 a
go
ni
st
Ve
hi
cle 7E
3
10
E5
P4
C1
0
12
G1
0
LM
60
9
23
C6
A
d
h
e
re
n
t 
P
la
te
le
ts
 (
x1
0
0
0
)
0
200
400
600
800
1000
1200 ATX 
FG 
ADP-Activated Platelets
B
 
Human platelet adhesion is inhibited by blocking integrins:  (A) Platelet adhesion to 
microtiter wells with immobilized ATX without (open bar) or with 10 μM ADP (closed 
circles) and the indicated concentrations of echistatin, an RGD-containing disintegrin.  
(B) Results obtained with platelets from one donor incubated with wells containing 
immobilized ATX (dark bars) or fibrinogen (gray bars; immobilized at 10 μg/ml) in the 
presence of 10 μM ADP and 20 μg/ml of a β3-blocking antibody (7E3), an αIIbβ3-
blocking antibody (10E5), a β1-blocking antibody (P4C10), a β1 antibody that has no 
effect on ligand binding (12G10), an αVβ3-blocking antibody (LM609), and an αVβ3 
antibody that has no effect on ligand binding (23C6). 
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FIGURE 2.9 
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Activated murine platelets adhere to ATX in β3-dependent manner:  Platelets were 
isolated from wild-type (Itgβ+/+) or Itgβ3-/- mice and incubated (200,000/μl) with wells 
containing immobilized ATX or fibrinogen in the presence of 150 μM PAR4 activating 
peptide. Results are representative of those obtained in 3 separate experiments. 
(*P<0.05 versus Itgβ+/+ platelets, 2-way ANOVA, ns = not significant). 
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FIGURE 2.10 
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CHO cells transfected with β3 integrin adhere to ATX:  Calcein-labeled CHO cells (300 
cells/μl) (control) or CHO cells that were stably expressing β3 or αIIbβ3 were incubated 
with immobilized ATX in the presence of 2mM CaCl2 and 1mM MgCl2 (open bars), 50 μM 
Mn2+ (black bars) or 50 μM Mn2 and 20 μg/ml of the function-blocking integrin β3 
antibody 7E3 (hatched bars). (*P<0.05 versus control CHO cells, ANOVA). Results are 
presented as the number of adherent platelets or CHO cells (mean ± SD) from triplicate 
determinations. 
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FIGURE 2.11 
 
Affinity and stochiometry of 125I-ATX binding to activated platelets.  (A)  15 M TRAP-
activated platelets (200,000/l) were incubated with a total of 73 nM ATX, composed of 
varying amounts of 125I-labeled ATX and unlabeled ATX and platelet bound ATX 
determined as described in the materials and methods.     (B)  TRAP-activated platelets 
were incubated with  125I-ATX for the indicated times.  At 30 min, echistatin (20 g/ml) 
was added and incubations continued  for an additional 30 min to determine 
reversibility. (C)  TRAP-activated platelets () or resting platelets () were incubated 
with the indicated concentrations of ATX for 30 min.  (D)  TRAP-activated platelets were 
incubated with [125I]-ATX in the presence of the indicated concentrations of fibrinogen.  
Data are means of duplicate determinations. 
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FIGURE 2.12 
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Non-lysoPLD effects of ATX on platelet aggregation:  (A) Gel-filtered platelets 
(200,000/μl) were stirred in the absence or presence of 200 μg/ml fibrinogen (+FG) or 
50 μg/ml ATXT210A (+ATX). Platelet aggregation was stimulated by the addition of 15 
μM TRAP at the time indicated by the arrow. (B) Gel-filtered platelets (200,000/μl) 
stirred in the presence of 200 μg/ml fibrinogen without ATX (FG – ATX) or with 50 μg/ml 
ATX (FG + ATX). 15 μM TRAP was added at the time indicated by the arrow. Left, 
representative light transmission tracing from single donor; right, cumulative maximal 
percent aggregation from different donors (*P <0.05, paired t-test). 
  
  
 
60 
FIGURE 2.13 
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FIGURE 2.13 (CAPTION) 
Non-lysoPLD effects of ATX on platelet adhesion.  Platelets (20,000/μl) were incubated 
with wells pre-coated with either 1 μg/ml or 5 μg/ml.  (A) Where indicated plates were 
coated with ATX or FG and adherent platelets were stained with TRITC-phallodoin.  
Platelets were visualized by widefield fluorescent microscopy.  (B) The total number of 
platelets/field in 4-5 fields were counted. Where indicated, the number of platelets 
adherent in the presence of soluble ATX was also determined. The platelets in each field 
were scored as fully spread (defined by the presence of cortical actin reorganization), 
partially spread (presence of filopodia) or unspread (neither cortical actin or filopodia). 
(*P <0.05, One way ANOVA on total number of adherent platelets). 
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FIGURE 2.14 
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The SMB domain of ATX possesses integrin-binding capacity:  (A) Human platelets 
were incubated with immobilized ATX or the N-terminal SMB1-2 fragment in the 
presence of 2 mM CaCl2 and 1 mM MgCl2 alone (open bars), with 10 μM ADP (black 
bars), or with 10 μM ADP and 20 μg/ml of the function blocking integrin β3 antibody 7E3 
(hatched bars). (B) CHO cells stably expressing the human β3 integrin subunit were 
incubated with immobilized ATX or the N-terminal SMB1-2 fragment in the presence of 
2mM CaCl2 and 1mM MgCl2 (open bars), 50 μM MnCl2 (black bars) or 50 μM MnCl2 and 
20 μg/ml 7E3 (hatched bars). Data shown are means ± SD of triplicate determinations. 
 
(A) modified from Hausman et al146. 
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FIGURE 2.15 
 
ATX activity against exogenously provided and cell-associated substrates is increased 
by integrin binding.    (A)  Control or IIb3 expressing CHO cells were incubated with 
100 nM ATX in Tyrode’s buffer containing 1 mM MgCl2, 50 μM MnCl2,, 100 M C17 LPC, 
and 0.35% BSA.  Production of C17 LPA was measured after a 1 hour incubation at 37°C.   
(B,C)  Control or IIb3 expressing CHO cells were preincubated with bee venom PLA2 
to increase LPC production (B) and then incubated with the indicated concentrations of 
ATX in the Tyrode’s buffer used for the experiment shown in panel (A) omitting the C17 
LPC and production of LPA determined as described in the materials and methods.  (D)  
IIb3 expressing CHO cells were preincubated with bee venom PLA2 and then 
incubated with the indicated concentrations of ATX in the Tyrode’s buffer in the 
presence or absence of 10 g/ml of the integrin blocking antibody 7E3 and production 
of LPA determined as described in the materials and methods.  The data shown are 
means ± SD of triplicate determinations (A) or duplicate determinations (B,C). 
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FIGURE 2.16 
 
ATX SMB2 mutants with impaired binding to β3 integrins display reduced LPA 
generating capacity. (A) Binding of β3 integrin expressing CHO cells to wild type ATX 
and the indicated ATX variants was determined as described in the materials and 
methods (mean ± SD of triplicate determinants). (B) The effect of wild type ATX and ATX 
E019A on LPA production by thrombin stimulated platelets was determined as described 
in the materials and methods (mean ± SD of triplicate determinations). 
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FIGURE 2.17 
 
Current Model.  Recruitment of ATX to the cell surface by activated integrins enables 
localized production of LPA by hydrolysis of cell surface lysophospholipid substrates. 
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CHAPTER 3:  LPA4 SIGNALING IN MURINE PLATELETS 
INTRODUCTION 
Among the effects LPA has on vascular and blood cells described in Chapter 1, LPA acts 
as an agonist to human platelets.  Activation of human platelets by LPA likely involves 
G12/13 stimulation of the GTPase Rho, which regulates myosin light chain kinase and 
actin reorganization leading to shape change125, 127.  Reports vary on the extent to which 
LPA elicits intracellular Ca2+ release in platelets129, 176.  LPA can also activate tyrosine 
kinases SRC and SYK in platelets176.  Higher concentrations of LPA are required to 
activate platelets in whole blood than those effective at activating isolated platelets, 
which may be due in part to sequestrations of LPA by plasma albumin or gelsolin or by 
the metabolism of LPA by blood cell-associated LPPs177.  Additionally, ADP receptor 
antagonists block LPA-induced platelet aggregation in whole blood, indicating that 
released ADP potentiates platelet LPA responses127. 
The identity of the stimulatory human platelet LPA receptor(s) has not been established.  
Human platelets contain mRNAs for LPA1-520, 130, 172.  Interestingly LPA species with 
alkyl-linked and highly unsaturated radyl chains are uniquely potent platelet activators98, 
99, 178.  This unusual pharmacology is not observed with recombinant LPA1-4 expressed 
in heterologous expression systems, indicating that these receptors are unlikely to be 
primary mediators of the major stimulator effects of LPA on human platelets.  LPA has 
also been proposed as an endogenous activator of PPARγ and intravascular infusion of 
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LPA appears to affect smooth muscle cell function through PPARγ179.  In platelets, 
activation of PPARγ has been associated with inhibition of platelet function180. 
We and others have reported that platelets from a subset of normal donors (~20%) fail 
to aggregate in response to LPA98, 172.    Lack of LPA-induced aggregation in LPA-
nonresponsive individuals is associated with the presence of an LPA-promoted 
inhibitory signaling response in platelets, and interestingly individuals with coronary 
artery disease are more likely to have LPA-responsive platelets172.  The presence of LPA-
mediated inhibitory signals may explain the variability among different human donors 
observed in platelet responses to LPA.  Among the LPA receptors expressed in human 
platelets, LPA4 and LPA5 are the most abundant and are indeed among the most 
abundantly expressed of all platelet GPCRs20, 172, 181.  We have found that the subset of 
donors who fail to aggregate in response to LPA have higher expression levels of 
LPA4172.  Finally, in contrast to the majority of human platelets, LPA inhibits agonist-
activation of mouse platelets49. 
We predict that differential expression levels of LPA4 and LPA5 explains the difference 
in LPA responsive between murine platelets and platelets derived from most human 
donors as well as the difference noted between human responders and non-responders.  
Since LPA4 expression levels are higher in human non-responders and LPA4 is capable of 
coupling to Gs increasing cAMP levels in cultured cell systems100, we hypothesized that 
LPA4-dependent signaling is responsible for inhibitory signals of LPA.  We likewise 
predicted that the most significant LPA-dependent platelet-activating pathway is via 
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LPA5.  This is because LPA5 is the second most abundant transcript found in platelets181 
and  preferentially binds to alkyl-LPAs which are more potent platelet agonists than acyl-
LPAs99, 182. 
Led by Julie Oestreich, PharmD, PhD, we began to investigate these signaling pathways 
using complementary methods.  One of these methods involved investigation of the role 
of LPA5 in human platelet aggregation using bromophosphonate-based LPA mimetics 
(BrP-LPA).  These compounds have a chiral center and exist to one of two enantiomeric 
forms.  The anti form of the compound is a pan-LPA receptor antagonist (for LPA1-5).  
The syn form of the compound also shows antagonism for LPA1-4 but partial agonism 
for LPA5183.  We have previously conducted studies to evaluate the effects of these 
compounds on human platelet aggregation and found that syn-BrP-LPA, the partial LPA5 
agonist, induces promotes platelet aggregation (Figure 3.1) while anti-BrP-LPA inhibits 
agonist-depndent and specifically LPA-dependent aggregation (Figure 3.2) (Julie 
Oestreich and Susan Smyth, unpublished data).  This supported the hypothesis that 
LPA5 plays a stimulatory role in platelet signaling.  To further investigate the role of 
these receptors in platelet signaling, we also investigated platelet activation and 
thrombosis is LPA4-deficient mice (lpa4-/-).  In whole blood aggregation assays of lpa4-
/- platelets were slightly more prone to aggregate in the presence of moderate doses of 
a PAR4 agonist peptide (AYPGKF) at moderate concentrations (Figure 3.3A).  The lpa4-/- 
platelets also exhibited slightly more P-selectin expression (Figure 3.3B) although in this 
case the results were not statistically significant (Smyth, unpublished).  LPA had only 
moderate effects on isolated murine platelets, but we nonetheless sought to evaluate 
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whether there was an in vivo thrombotic phenotype.  While blood counts were identical 
in wild type (WT) vs lpa4-/- animals (Table 3.1), lpa4-/- mice displayed a pro-thrombotic 
phenotype during a ferric chloride (FeCl3)-induced carotid artery thrombosis (Figure 3.4) 
(Smyth, unpublished). 
In light of these findings, I continued to evaluate our hypothesis that platelet LPA4 
mediates a predominately inhibitory pathway. 
METHODS 
Mice 
All procedures conformed to the recommendations of the “Guide for the Care and Use 
of Laboratory Animals” (Department of Health, Education, and Welfare publication no. 
NIH 78-23, 1996) and were approved by the Institutional Animal Care and Use 
Committee. Mice were weaned at 21 days, maintained on a 12-h light and 12-h dark 
cycle, and fed water and standard rodent chow (2018 Harlan Tekland Rodent Diet) ad 
libitum.  Mice were originally received as a generous gift from Xianjun Fang (Virginia 
Commonwealth University).  The null mice were produced by deletion of the 3′ portion 
of intron 2 and the 5′ fragment of exon 3 of the lpa4 gene as described in Lee et al.101 
We maintained the mice on a mixed 129/Sv and C57BL/6 background. 
Blood Collection 
Blood was collected from healthy donors with approval from the Institutional Review 
Board at the University of Kentucky by cubital venipuncture with a 19 gauge needle and 
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collected into citrate (final citrate concentration was 0.38%). For studies of isolated 
murine platelets, we collect blood by retrooribital puncture performed under anesthesia 
as previously described163. 
Preparation of Platelets 
Citrated human blood was centrifuged at 450 x g for 5 minutes to yield platelet rich 
plasma (PRP), to which 134 nM prostaglandin I2 (PGI2) was added. Platelets were 
separated from plasma by filtration of PRP using a column of Sepharose 2B (Sigma) 
equilibrated in HEPES-buffered modified Tyrode’s buffer (138 mM NaCl, 5.6 mM 
dextrose, 2.7 mM KCl, 10 mM HEPES, 12 mM NaHCO3, 0.36 mM NaH2PO4, pH 7.35) with 
0.35% fatty acid-free BSA (US Biological) . For adhesion assays, PRP was incubated with 
7 μM calcein AM for 30 minutes at 37°C prior to gel-filtration. Unless otherwise 
indicated, gel-filtered platelets were diluted to 200,000 /μl in Tyrode’s containing fatty 
acid free (ethanol and charcoal extracted) BSA (Sigma Aldrich). 
Bone marrow transplantation 
Recipient mice (C57BL/6 background) were γ-irradiated with cesium-137 as the 
radiation source (Mark I Irradiator).  The first radiation dose was 7 Gy (700 rad).  Donor 
mice were then anesthetized and euthanized with isoflurane followed by cervical 
dislocation.  They were sterilized by submersion in 70% ethanol and the femurs and tibia 
were isolated into sterile PBS.  Following isolation, the ends of the long bones were cut 
off and a 27.5 gauge needle was used to flush isolation media (RPMI media 
supplemented with 10mM HEPES, 25 U/mL heparin and 5% FBS) until bone marrow was 
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completely removed.  The bone marrow components were pelleted using an Eppendorff 
5810 R centrifuge at 1500 RPM at 4°C for 10 minutes.  The pellet was resuspended in 3 
ml 0.2% saline to lyse the erythrocytes for 45 seconds followed by addition of 7 ml 1.2% 
saline to stop the lysis.  The cells were pelleted once more and resuspended to ~50 x 106 
cells/mL in PBS supplemented with 2% heat-inactivated FBS.  The recipient mice were 
then given a second radiation dose of 5 Gy (500 rad) which occurred at least 3 hours 
after the first dose.  Following the second radiation dose, the recipient mice were 
injected with the prepared bone marrow-derived cells from the donor mice (~5 x 106 
cells/recipient). 
Fibrinogen Binding 
Mice were anesthetized with isoflurane, and blood was collected by puncture of the 
retrobulbar venous plexus into tubes containing 1/10th the volume of 3.2% sodium 
citrate (final concentration of 0.32% citrate).  Citrated blood was then diluted 1:40 into 
Tyrode’s buffer (138 mM NaCl, 5.6 mM dextrose, 2.7 mM KCl, 10 mM HEPES, 12 mM 
NaHCO3, 0.36 mM NaH2PO4, pH 7.35) with 0.35% fatty acid-free BSA (US Biological).  
Prior to use 1 mM MgCl2 was added to the diluted blood.  18 µl of blood was added to 9 
µl of FITC-anti-FG (Dako) which had been diluted 1:10 in Tyrode’s + BSA + MgCl2 and 3 µl 
of 10x agonist.  Following a10-minute incubation, reactions were stopped by adding 500 
µl Tyrode’s + BSA + MgCl2 and 500 µl 4% paraformaldehyde in PBS.  Fibrinogen binding 
was determined by fluorocytometric analysis (BD FACSCalibur Flow Cytometer; 342975).  
In experiments which involved evaluating the effects of LPA, LPA stocks (in chloroform) 
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were dried and then reconstituted in Tyrode’s + BSA by successive vortexing and 
sonicating. 
Platelet Aggregation 
For light transmission aggregometry, isolated platelets were prepared by gel filtration 
into Tyrode’s with BSA as described above and diluted to 200,000 /µl.  2 mM Ca2+ and 1 
mM Mg2+ was added as was fibrinogen where indicated.  400 µl isolated platelets were 
aggregated using the indicated agonists at 37°C under stirring conditions.  Aggregation 
was measured by light transmission (Platelet-Ionized Calcium Aggregometer; Model 
660; Chrono-log).  For whole blood aggregation, blood was collected into hirudin and 
diluted 1:1 with normal saline.  300 µl diluted blood were added to test wells, and 
aggregation was determined by recording electrical impedence (Multiplate; Model 
MP0010, Dynabyte Medical). 
Static Platelet Adhesion 
Recombinant type I collagen (from rat tail; BD) or fibrinogen (American Diagnostica) 
diluted in Tris buffer (50 mM Tris, 100 mM NaCl, pH 7.4) was incubated in wells of an 8-
well coverslip chamber (LabTek2) overnight at 4°C. The wells were subsequently 
incubated for 1 hour at room temperature with Tyrode’s containing BSA to block non-
specific binding sites.  Platelets were diluted to 20,000 /μl in Tyrode’s containing BSA 
and 1 mM Mg2+ and allowed to adhere to wells for one hour at 37°C.  Non-adherent 
platelets were removed by successive washings with Tyrode’s containing BSA and 1 mM 
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Mg2+ and adherent platelets were fixed with 4% paraformaldehyde, permeabilized, and 
stained with TRITC-phalloidin.  
Carotid Artery Thrombosis 
4% FeCl3 (247 mM) solution was prepared in normal saline on the day of use.  Mice were 
anesthetized with inhaled isoflurane (1-2.5%), and their body temperature was 
maintained at 37°C by varying the output of an EPZ type halogen heat lamp. A flow 
probe (Model 0.5 PSB, Trnasomic System, Inc.) was placed on the left carotid artery.  
Thrombosis was initiated by the application of two 1 – 2-mm pieces of filter paper 
(Whatman no. 3) on opposite sides of the carotid artery that had been submerged in the 
FeCl3 solution for 5 seconds just prior to application.  The filter paper was removed after 
3 minutes.  The flow probe was used to record the time thrombotic occlusion, which 
was defined as the time to complete cessation of blood flow for at least 30 seconds. 
Cytokine Assays 
Membranes impregnated with cytokine antibodies (RayBiotech) were blocked in PBS + 
0.1% casein at 4°C overnight.  The membranes were then incubated with mouse plasma 
for 2 hours at room temperature and washed thrice with PBS + 0.1% tween.  The 
membranes were then incubated with biotin-conjugated cytokine antibodies 
(RayBiotech) for 2 hours at room and washed 4 times with PBS + tween.  Finally the 
membranes were incubated in the dark with IRDye 800CW-conjugated streptavidin (LI-
COR) for 2 hours at room temperature and washed thrice with PBS + tween and then 
twice with PBS. 
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Statistics 
Statistical analyses and preparation of figures were conducted using SigmaStat and 
SigmaPlot, respectively.  Specific statistical tests are indicated in figure legends. 
RESULTS 
Binding of Fibrinogen is Not Altered in lpa4-/- Platelets 
LPA typically acts as an agonist in human platelets while LPA is refractory to activation in 
murine platelets.  The agonistic or antagonistic activity may be due to relative levels of 
LPA4 expressed by platelets.  In our preliminary studies (described in the previous 
section) we found only mild to no differences in activation of lpa4-/- platelets compared 
to WT platelets using a whole blood aggregation assay and PAR4-stimulating peptide or 
collagen as an agonist.  We sought to find if there were more subtle differences in 
platelet activation as specifically measured by fibrinogen binding.  Histograms based 
upon fibrinogen binding (Figure 3.5A) showed no clear difference between lpa4-/- 
platelets or WT platelets whether evaluated by the percentage of platelets to have 
positive fibrinogen binding as indicated by fluorescence above a pre-set threshold 
(Figure 3.5B left), evaluated by the geometric mean (Figure 3.5B right), or evaluated by 
any other measure of central tendency (not shown).  Similarly, no difference between 
lpa4-/- platelets and WT platelets was noted when platelets were exposed to 10 µM 
oleyl LPA and agonist (Figure 3.6A, B). 
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lpa4-/- Platelets Adhere More Strongly to Collagen than WT Platelets 
We further sought to evaluate the ability of lpa4-/- platelets to adhere to different 
adhesive proteins.  We were particularly interested in this since our earlier studies 
suggested that lpa4-/- mice were prone to thrombosis with FeCl3.  Platelets derived 
from lpa4-/- mice adhered to fibrinogen in a comparable manner as did platelets 
derived from WT mice (Figure 3.7A, B).  Interestingly, lpa4-/- platelets from older mice 
(~2 years) adhered to collagen a greater extent than platelets from age-matched WT 
littermate mice (Figure 3.7B, C).  However, platelets derived from younger lpa4-/- mice 
(~3 months) did not show increased absolute numbers of adherent platelets to collagen 
compared with age-matched WT controls.  The amount of platelet spreading did 
increase in lpa4-/- mice compared with WT mice (although not to a point that was 
statistically significant) (Figure 3.8C).  We therefore hypothesized that any differences 
we saw in the ability of lpa4-/- platelets and WT platelets to adhere to collagen was due 
to differences in the platelet levels of GPVI, the major collagen receptor which facilitates 
signaling.  To evaluate this, we used a FITC-labeled anti-GPVI monoclonal antibody to 
evaluate levels of GPVI on lpa4-/- and WT platelets by fluorocytometry and found no 
difference in the levels of GPVI (Figure 3.8A, B) 
Mice with lpa4-/- Derived Bone Marrow Are Protected from Thrombosis 
Our earlier data suggested that lpa4-/- mice had a thrombotic tendency.  Likewise lpa4-
/- platelets seem to adhere more efficiently to immobilized collagen although 
aggregation and fibrinogen binding assays showed little to know difference in activation 
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response of lpa4-/- platelets when compared with WT mice.  This raised the distinct 
possibility that the observed pro-thrombotic phenotype could be due to LPA4 receptors 
in cells aside from platelets.  Expression of lpa4 has been reported in endothelial cells103.  
We therefore generated chimera mice by lethally irradiating recipient mice and rescuing 
them with bone marrow derived from lpa4-/- mice or WT mice.  In general, complete 
blood counts were similar between mice reconstituted with lpa4-/- bone marrow and 
WT bone marrow (Table 3.2). Not surprisingly, all irradiated mice developed a relative 
pancytopenia when compared with non-irradiated mice (Table 3.1 and Table 3.2).  After 
conducting thrombosis experiments on these chimeras, we found that animals 
transplanted with WT platelets were more prone to thrombosis than animals 
transplanted with platelets from lpa4-/- donor mice with non-transplanted mice 
exhibiting an intermediate phenotype (Figure 3.9).  This was in stark contrast to the 
thrombosis experiments conducted previously in global lpa4-/- mice which exhibited a 
pro-thrombotic phenotype (Figure 3.4). 
Despite this discrepancy, there is a clear effect that LPA4 plays on thrombosis.  It is not 
currently clear whether LPA4 plays a protective role or deleterious role.  In any case, the 
effect is not likely to be due to platelet LPA4 in these animals since isolated platelets 
have little to no appreciable phenotype in aggregation, flow cytometry, or adhesion.  
We therefore evaluated cytokine levels in these mice using antibodies against a variety 
cytokines related to atherosclerosis.  No differences were appreciated between the two 
genotypes (Table 3.3). 
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DISCUSSION 
LPA has typically been characterized as a weak platelet agonist although we have found 
previously that in some humans, LPA is refractory to platelet activation172 as it is in 
murine platelets49.  This stimulatory activity of LPA on human platelets seems to involve 
LPA5 because LPA stimulatory effects are elicited by an LPA mimetic that has partial 
agonist activity at LPA5 but is antagonistic to other LPA receptors183 (Figure 3.1).  This 
observation is consistent with earlier reports that alkyl-LPA, which acts more potently at 
LPA5, is a stronger platelet agonist than acyl LPAs98, 182.  Because LPA4 expression is 
abundant in human platelets20, has higher expression in humans whose platelets have 
refractory responses to LPA172, and can couple to Gs100, we surmised that this is likely 
the receptor responsible for LPA-dependent platelet inhibition.  Because LPA acts as an 
inhibitor to murine platelets, we used an lpa4-/- mouse model to test the hypothesis 
that the inhibitory LPA signaling pathway is mediated by LPA4.  We evaluated their 
platelet responses in in vitro and in vivo settings. 
Earlier findings in our laboratory suggested that there was perhaps a moderate pro-
stimulatory phenotype in isolated lpa4-/- platelets (Figure 3.3), but the finding that was 
especially compelling was the in vivo thrombosis data using a FeCl3-injury model, a 
model that is collagen-dependent184.  Lpa4-/- mice exhibited a substantially pro-
thrombotic phenotype compared with WT mice (Figure 3.4).  As I began evaluating 
these pathways, again using isolated platelets, I could not find any differences in 
stimulatory signaling in platelets derived from lpa4-/- mice compared with those 
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derived from WT mice (Figure 3.5 and Figure 3.6).  I sought also to look at inhibitory 
pathways by measuring the phosphorylation of vasodilator-stimulated protein, a marker 
of platelet inhibition, via Western blotting and flow cytometry although sufficient signal 
strength was never achieved to draw any conclusive results (data not shown).  In short, 
very few of the studies I conducted on isolated platelets yielded significant results.  
Indeed one of the only assays I conducted that displayed a difference between lpa4-/- 
platelet and WT platelets was adhesion to collagen (Figure 3.7), and even then the 
results were age-dependent and only suggestive.  Since there was a modest effect of the 
LPA4 receptor on collagen adhesion, I decided to go back to the FeCl3 (collagen-
dependent model).  This time instead of using global knockouts, I decided to look at the 
effect of LPA4 receptors specifically in bone marrow-derived cells.  This, I hoped, would 
yield more-platelet specific information.  As described in the previous section, the 
thrombosis data in these chimeras were paradoxically the exact opposite of our 
laboratory’s earlier observations in global knockouts.  Chimeras that were transplanted 
with lpa4-/- bone marrow were actually protected from thrombosis rather than being 
prone to thrombosis (Figure 3.9). 
It is difficult to reconcile the difference in these findings if one were to use a platelet-
centric view point.  Interestingly, although LPA receptors and LPA responses have clearly 
been identified in human platelets, the same cannot be said for mouse platelets with 
the exception of our laboratory’s earlier findings that LPA inhibits platelet activation49.  
Recently, a non-biased evaluation of the platelet transcriptome of both humans and 
mice revealed that most LPA receptor transcripts are present in human platelets20.  In 
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stark contrast to this there were no LPA receptor transcripts expressed in murine 
platelets with the exception of exceedingly small levels of lpa4 which itself was at the 
threshold of detectability20.  Over the course of these studies, we attempted to directly 
evaluate LPA4 protein levels, although like many membrane-bound proteins, it proved 
difficult to evaluate.  There is a clear presence of a phenotype using in vivo thrombosis 
and a lack of a phenotype in isolated platelet activity assays.  This indicates that the role 
that LPA4 plays in thrombosis is actually in a cell type different than platelets.  LPA4 
expression has been reported in endothelial cells103 making this a likely candidate for 
being responsible for some of the thrombosis phenotypes seen when comparing lpa4-/- 
thrombosis with WT thrombosis.  Even in the chimeric animals, it is certainly plausible 
that some of the endothelial cells were actually devoid of LPA4 in the animals 
transplanted with lpa4-/- bone marrow.  The chimeras were produced by lethal 
irradiation and undoubtedly had endothelial damage which may have been replaced by 
LPA4-deficient cells as there have been reports that circulating endothelial progenitor 
cells are bone marrow-derived185.  In the chimeras, injury itself promoted thrombosis as 
chimeras reconstituted with WT bone marrow were more prone to exhibit full occlusion 
than non-irradiated mice (Figure 3.9).  If anything, LPA4-depletion seemed to protect 
animals from this radiation-dependent injury and subsequent propensity toward 
thrombosis.  This suggests that a number of different mechanisms involving 
inflammatory responses, fibrosis, etc. may be dependent on LPA4 in one or more yet-to-
be-identified cells.  An attempt to elucidate such factors by evaluating soluble cytokines 
did not yield any striking findings (Table 3.3). 
  
 
80 
In conclusion, while the LPA4 receptor plays an important, if still ambiguous role, in 
thrombosis, this may or may not be due specifically to platelet LPA4.  The assays 
presented here involving isolated platelets did not identify a specific role for LPA4 in 
contrast to our earlier paper that identified an inhibitory role of LPA in murine 
platelets49.  When these observations are viewed in light of the extremely small levels of 
LPA4 transcript identified in murine platelets20, the most reasonable explanation is that 
very slight changes in LPA4 expression in murine platelets could result in vastly different 
responses of murine platelets to LPA and other stimulator and/or inhibitory agents.  
These could all be dependent upon mouse strain, sex, age, and environmental 
variations.  Indeed phenotypes as severe as embryonic mortality are starkly different in 
LPA4-deficient mice derived in different laboratories101, 103, so differences in platelet 
function are certainly plausible.  It is still very likely that in humans, LPA4 is responsible 
for a platelet-inhibitory pathway while LPA5 promotes platelet activation.  Murine 
models may simply not be a good model to investigate these given the extreme scarcity 
of these receptors when compared with human platelets. 
Future work in this area would necessarily include understanding the relative role of 
vascular cells and blood cells using a number of different chimeras (WT to lpa4-/-, lpa4-
/- to WT, etc.).  To further understand the relative roles of LPA4 and LPA5 in humans, an 
additional investigatory tool would be knock-in mice that express significant levels of 
human LPA4 and/or human LPA5 (either specifically in bone marrow-derived cells using 
a viral vector or a global genomic knock-in).   
Copyright © Zachary B. Fulkerson 2011 
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TABLE 3.1 
Genotype n 
WBC 
(K/ml) 
Hct (%) Hgb (g/dL) 
Platelet 
(K/ml) 
Wild-type 9 6.5 ± 0.9 46 ± 2 12 ± 0.4 695 ± 78 
Lpa4-/- 9 7.7 ± 0.7 44 ± 1 12 ± 0.3 656 ± 42 
 
Complete blood counts of wild-type and lpa4-/- mice. 
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TABLE 3.2 
Genotype n 
WBC 
(K/ml) 
Hct (%) Hgb (g/dL) 
Platelet 
(K/ml) 
Wild type 6 12.0 ± 1.8 26.4± 5.6±1.6 476± 119 
Lpa4-/- 6 11.1 ± 2.0 27.4± 6.1±1.7 645 ± 80 
 
Complete blood counts of chimera mice transplanted with bone marrow from wild-
type and lpa4-/- mice. 
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TABLE 3.3 
 
 Lpa4-/- 
   
 WT 
  GCSF  0.230 ± 0.006 
 
 0.225 ± 0.006 
IL-5  0.072 ± 0.032 
 
 0.035 ± 0.000 
RANTES  0.083 ± 0.004 
 
 0.077 ± 0.004 
GM-CSF  0.110 ± 0.000 
 
 0.105 ± 0.003 
IL-6  0.042 ± 0.003 
 
 0.042 ± 0.003 
TNFα  0.127 ± 0.004 
 
 0.113 ± 0.008 
IFNγ  0.177 ± 0.122 
 
 0.052 ± 0.002 
IL-13  0.098 ± 0.004 
 
 0.088 ± 0.002 
VEGF  0.018 ± 0.003 
 
 0.018 ± 0.002 
IL-1α  0.048 ± 0.002 
 
 0.052 ± 0.003 
L-Selectin  0.558 ± 0.016 
 
 0.515 ± 0.020 
IL-1β  0.097 ± 0.007 
 
 0.088 ± 0.009 
MCP1  0.093 ± 0.003 
 
 0.078 ± 0.006 
FGF basic  0.225 ± 0.110 
 
 0.107 ± 0.009 
IL-2  0.025 ± 0.003 
 
 0.022 ± 0.002 
M-CSF  0.093 ± 0.003 
 
 0.085 ± 0.006 
CD40  0.068 ± 0.004 
 
 0.062 ± 0.003 
IL-3  0.070 ± 0.003 
 
 0.065 ± 0.006 
MIP-3α  0.113 ± 0.003 
 
 0.097 ± 0.010 
Eotaxin   0.017 ± 0.002 
 
 0.015 ± 0.005 
IL-4  0.102 ± 0.006 
 
 0.098 ± 0.012 
P-Selectin  0.273 ± 0.019 
 
 0.218 ± 0.028 
 
Atherogenic Cytokines Unaffected in lpa4-/- Mice:  Levels of select atherogenic 
cytokines were ascertained in platelet-poor plasma derived from lpa4-/- mice (left) and 
WT littermates (right).  Values indicate mean intensity and standard deviation for each 
group.  N = 3 for each group.  No cytokines showed statistically significant differences 
using a Student’s t-test. 
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FIGURE 3.1 
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Agonism of LPA5 Promotes Aggregation.  Light transmission aggregation of human 
platelets after isolation by gel-filtration.  Platelets were treated with vehicle or 10 µN 
syn-BrLPA analog immediately prior to the addition of 20 µM ADP.  (A) Representative 
tracing from a single donor.  (B)  Cumulative maximal percent transmission from 
multiple donors.  P = 0.08 (Paired t test). 
 
Oestreich and Smyth, unpublished. 
  
  
 
85 
FIGURE 3.2 
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LPA Pan-antagonism Inhibits Aggregation.  Light transmission aggregation of human 
platelets after isolation by gel-filtration.  Platelets were treated with vehicle or 10 µN 
syn-BrLPA analog immediately prior to the addition of 20 µM ADP.  (A) Representative 
tracing from a single donor.  (B)  Cumulative maximal percent transmission from 
multiple donors.  P = 0.06 (Paired t test). 
 
Oestreich and Smyth, unpublished. 
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FIGURE 3.3 
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Platelet Activation in lpa4-/- mice.  (A) Whole blood aggregation of mice treated with a 
peptide agonist to the PAR4 receptor (AYPGKF) at the indicated concentrations or with 
10 µg/ml collagen.  AT 150 µM AYPGKF p = 0.05 (Student t-test).  (B)  P-selectin 
expression measured by flow cytometry in ploatelets treated with AYPGKF at the 
indicated concentrations. 
 
Smyth, unpublished. 
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FIGURE 3.4 
 
lpa4-/- mice have a prothrombotic phenotype:  FeCl3-induced thrombosis of the left 
carotid artery in animals with a global deletion of the LPA4 receptor (Lpa4-/-; dashed 
line) and WT controls (solid line).  * p = 0.003 Log-rank test. 
 
Smyth, unpublished. 
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FIGURE 3.5 
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lpa4-/- Platelets Have Normal Fibrinogen Binding Response to Agonists:   A FITC-
conjugated anti-fibrinogen antibody was used to evaluate fibrinogen binding to 
platelets.  (A) Representative histograms of lpa4-/- (red) and WT (blue) platelets 
incubated with ADP or a PAR4 agonist peptide (AYPGKF) at the indicated concentrations.  
The vertical line indicates the threshold for labeling a platelet as having positive 
fluorescence.  (B)  Cumulative data of fibrinogen binding for platelets from lpa4-/- mice 
(black bars; n = 3) and WT platelets (gray bars; n = 4) after stimulation.  The left panel 
indicates the fraction of platelets having positive fluorescence.  The right panel shows 
the geometric mean fluorescence.  Any differences lpa4-/- and WT fibrinogen binding 
(fluorescence) were not statistically significant. 
  
B 
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FIGURE 3.6 
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lpa4-/- Platelets Have Normal Fibrinogen Binding Response to Agonists with LPA:   A 
FITC-conjugated anti-fibrinogen antibody was used to evaluate fibrinogen binding to 
platelets.  (A) Representative histograms of lpa4-/- (red) and WT (blue) platelets 
incubated with 10 µM oleyl LPA and/or ADP or a PAR4 agonist peptide (AYPGKF) at the 
indicated concentrations.  The vertical line indicates the threshold for labeling a platelet 
as having positive fluorescence.  (B)  Cumulative data of fibrinogen binding for platelets 
from lpa4-/- mice (black bars; n = 3) and WT platelets (gray bars; n = 4) after stimulation.  
The left panel indicates the fraction of platelets having positive fluorescence.  The right 
panel shows the geometric mean fluorescence.  Any differences lpa4-/- and WT 
fibrinogen binding (fluorescence) were not statistically significant. 
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FIGURE 3.7 
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FIGURE 3.7 (CAPTION) 
lpa4-/- Platelets Have Increased Binding to Collagen:   Adhesion of murine platelets to 
platelets coated with either 10 µg/ml collagen or 5 µg/ml fibrinogen (FG).  (A)  Light 
micrographs showing adhesion of platelets stained with TRITC-phalloidin.  Platelets 
were acquired from mice approximately 2 years old.  (B)  Quantification of the number 
of platelets per high-powered field (HPF) shown in panel (A).  Scoring was also 
conducted based on the degree of spreading.  Left:  adhesion to collagen.  Right:  
adhesion to fibrinogen.  (C)  Quantification and scoring of platelets derived from mice 
approximately 3 months old adhering to collagen.  * p < 0.05 Student t test.   
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FIGURE 3.8 
 
IgG anti-GPVI
%
 P
o
si
ti
ve
0
20
40
60
80
100
lpa4-/-
WT 
B
IgG anti-GPVI
Lo
g 
M
e
an
 F
lu
o
re
sc
e
n
ce
0.0
0.2
0.4
0.6
0.8
lpa4-/-
WT 
 
lpa4-/- Platelets Have Normal Levels of GPVI:   A FITC-conjugated anti-GPVI antibody 
was used to evaluate GPVI in platelets.  (A) Representative histograms of lpa4-/- (red) 
and WT (blue) platelets incubated with control IgG (lighter color) or anti-GPVI (darker 
color).  The vertical line indicates the threshold for labeling a platelet as having positive 
fluorescence.  (B)  Cumulative data of GPVI for platelets from lpa4-/- mice (black bars; n 
= 4) and WT platelets (gray bars; n = 4) after.  The left panel indicates the fraction of 
platelets having positive fluorescence.  The right panel shows the geometric mean 
fluorescence.  Any differences lpa4-/- and WT fluorescence were not statistically 
significant. 
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FIGURE 3.9 
 
 
Bone marrow-derived cells lacking LPA4 are protected from thrombosis:  FeCl3-induced 
thrombosis of the left carotid artery in lethally irradiated mice rescued with lpa4-/- bone 
marrow (long dash), lethally irradiated mice rescued with WT bone marrow (solid line), 
or non-irradiated mice (short dash). *P = 0.002 Log-rank test. 
 
 
0
20
40
60
80
100
0 5 10 15 20
%
 M
ic
e
 w
it
h
 C
o
m
p
le
te
 O
cc
lu
si
o
n
 
Time (min) 
WT Chimera
Lpa4-/- Chimera
Untrasfected
* 
  
 
94 
CHAPTER 4:  DISCUSSION 
In this dissertation, I have discussed two aspects of LPA as they relate to platelets: the 
role of platelets in LPA production (Chapter 2), and the role of LPA in platelet signaling 
(Chapter 3).  In Chapter 2, interpretation of the results was largely offered in context of 
the specific molecular interactions (ie, ATX-integrin interactions) which govern the 
lysoPLD activity of ATX and localization of its product.  In Chapter 3, I specifically 
discussed the roles of LPA5 and LPA4 (especially the latter) in platelet LPA signaling.  In 
this particular section, a slightly broader perspective will be taken as we consider the 
overarching implications of these findings. 
ATX AND LPA IN PHYSIOLOGY AND PATHOPHYSIOLOGY 
Before beginning a discussion on a potential role of ATX or LPA in health and disease, it 
is important to consider where these signaling functions have physiological and 
pathophysiological effects, particularly in the vasculature.  In the plasma, LPA is present 
at micromolar concentrations46, 48 although interestingly it is unknown what the role of 
this global circulating LPA is in a normal physiological setting.  The plasma levels of LPA 
are tightly dependent on its relative production by ATX and degradation by the LPPs49, 
52.  However, whether LPA is serving a specific signaling purpose in the mature vascular 
system (eg, maintaining vascular tone) or is simply an intermediate step in the 
degradation of LPC is still not understood.  There have been reports that global 
intravenous administration of LPA has effects on vascular tone69 and even effects on the 
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progression of atherosclerosis in animal models115.  These findings do raise some 
interesting mechanistic oddities since the rapid turnover of LPA would result in near-
immediate removal of LPA added as a bolus52.  Nonetheless, the findings suggest that 
the large pool of circulating LPA may have an important role in the vasculature.  An 
additional peculiarity in human disease is that the venom of the brown recluse spider 
(Loxosceles reclusa) is a lysoPLD which produces measurable LPA186, 187, suggesting that 
there are serious implications if there are perturbations in LPA levels. 
Although the specific physiological role of LPA is not entirely understood in adults, the 
balance of LPA production and degradation seems to be critical for embryonic 
development as deletions of both ATX and LPP3 results in embryonic lethality with 
vascular defects54, 56, 57.  This implies that LPA has some effect in physiological or 
pathological vascular development in adults as well.  Of course, the ability of LPA to 
effect specific cellular processes would imply its ability either (1) to be generated in a 
precisely controlled manner, (2) to signal via receptors that are located on very specific 
cell types, or (3) to have complimentary actions with other specific cell-signaling 
entities.  A preliminary (and superficial) glance would suggest that the first scenario is 
unlikely to be the case since LPC and ATX are found at biologically significant levels in 
the plasma at all times.  The second scenario is also unlikely the case since LPA receptors 
are found ubiquitously on blood cells and vascular cells.  Finally the third option that LPA 
requires additional factors is unlikely since in in vitro settings, LPA is capable of eliciting 
cellular responses on its own. 
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IMPLICATIONS OF LOCALIZED LYSOPLD ACTIVITY 
Our own data, presented in Chapter 2, convincingly demonstrates the ability of ATX to 
bind to the surface of platelets, a process that is clearly mediated by the SMB-domain of 
ATX and integrins on the platelet surface.  This certainly forces reexamination of the first 
scenario mentioned above, that the production of LPA may be controlled spatially and 
temporally.  The PDE domain and the SMB domain form a portion of the proposed 
hydrophobic channel of ATX, by which LPC enters the active site and LPA leaves.  This 
indicates that integrin binding plays a role in regulating the catalytic activity of the 
enzyme itself.  This proposal is supported by our finding that BSA-associated substrate in 
the media is hydrolyzed more rapidly when platelet integrins are present and active 
(Figure 2.15A).  More than this, even when there is no (or negligible) BSA-bound 
substrate available for ATX to hydrolyze, ATX can not only access membrane substrates 
(Figure 2.4B, D) but it does so in an integrin-dependent manner producing membrane-
associated LPA (Figure 2.15C, D).  Once again, the question that arises is the importance 
of this membrane-associated LPA that is generated in a seemingly very controlled 
manner. 
It is reasonable to propose that the location of LPA dictates its signaling function – that 
there are actually different functional pools of LPA.  Perhaps the global plasma pool of 
LPA is nothing more of an intermediate in the metabolism of LPC.  Alternatively, plasma 
LPA could act globally on vascular tone or some other broad-reaching function.  In either 
case, membrane-associated LPA could certainly be poised to play a more selective 
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signaling role.  In platelets, it may be that ATX only gets recruited to the membrane 
surface when there is a certain level of integrin activation which would typically happen 
if there is underlying activation of the platelets themselves.  The effect of generating 
membrane-associated LPA could elicit robust and specific effects because (1) the LPA 
production is controlled spatially and temporally, (2) the local concentration of LPA 
could increase dramatically, and (3) being already located in the membrane, this pool of 
LPA may have much easier access to membrane LPA receptors (ligands for LPA receptors 
incorporate into the membrane-spanning hydrophobic region of the receptor188). 
Given a mechanism for how membrane-associated LPA is generated and how it may 
facilitate cell-specific (or platelet-specific) LPA signaling, the question again arises of 
what the ultimate functional consequences of this is.  In the context of platelets, there 
are a few possible scenarios which are not at all mutually exclusive.  Increased local 
production of LPA may facilitate changes in platelet responses to stress during the 
process of activation (ie, promotion or attenuation of platelet activation).  The data 
presented in Chapter 3 do indicate that in human platelets, LPA5 mediates stimulatory 
pathways.  The role of LPA4 is much more ambiguous as platelets isolated from lpa4-/- 
mice do not show a robust phenotype in various platelet function assays, and in vivo 
thrombosis oddly produces conflicting results if thrombosis is conducted in an animal 
with a global deletion of LPA4 or if the animal only has bone marrow-derived cells that 
lack LPA4.  Since LPA4 expression has been reported in the endothelium, it is likely that 
LPA-dependent interactions between platelets and endothelial cells plays an important 
role although the exact function still remains enigmatic. 
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In addition to facilitating LPA signaling in platelets specifically, the interaction of ATX 
with integrins may serve slightly different roles.  Since platelets are among the first 
blood components to localize to a site of injury, it is certainly feasible that LPA is 
delivered to these sites by activated platelets rather than exclusively acting on platelet 
LPA receptors.  In our own studies we found that LPA formed in isolated platelets 
tended to remain platelet-associated (data not shown).  However, these studies 
occurred in physiologic solutions that were devoid of lipoproteins and at most contained 
a maximum of 0.35% BSA.  Lipoproteins and BSA are both present at significant levels in 
the plasma, both are capable of associating with lysophospholipids.  It is therefore very 
possible that in vivo LPA could be sequestered from platelets and added to the global 
circulating pool or even to other cells.  This would explain the earlier findings in the 
literature that animals with thrombocytopenia have decreased circulating LPA58, 61. 
In addition to the possibility that platelets facilitate LPA delivery, it is further possible 
that ATX itself may be delivered to sites of injury.  Platelets are capable of not only 
binding the integrin ligand fibrinogen but also capable of internalizing fibrinogen upon 
binding189-191 which allows platelets to store up fibrinogen in granules and release it 
upon activation192.  Since ATX binds platelet αIIβ3 as fibrinogen, it is quite possible that 
platelets internalize, store, and secrete ATX in a manner identical to fibrinogen.  Our 
own data supports this hypothesis.  In earlier publications we found that platelets 
derived from WT mice had associated ATX (as measured by Western blot) while 
platelets derived from mice deficient in the β3 integrin subunit did not49.  While this in 
of itself does not indicate whether the ATX is externally associated with the platelet or 
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internalized, our lipid measurements in platelets (presented here in Chapter 2) 
uniformly show increased LPA production when the platelets were activated with 
thrombin even in the absence of exogenously added ATX.  We ultimately found that this 
thrombin-induced LPA production was indeed ATX-dependent (Figure 2.4). 
Again, the notion of ATX internalization and release does not exclude the role of integrin 
binding in localizing LPA production to the platelet itself and may indeed be a manner by 
which the effects of LPA are made even more cell-specific.  As platelets exocytose the 
contents of their granules, the local concentration of ATX could be dramatically 
increased and brought into proximity of the membrane and membrane-derived 
substrate when it binds to integrins.  At sites of injury, the integrins available with which 
ATX could interact would not merely be limited to platelet αIIbβ3.  The data presented 
in Chapter 2 indicate that ATX is capable of interacting with other αVβ3 as well as at 
least some integrins that incorporate a β1 subunit.  Integrin αVβ3 itself is fairly 
ubiquitously expressed on many cells including many cells in the blood and vasculature, 
so there is no reason that this phenomenon would be exclusive to platelets. Moreover, 
the binding of ATX to the surface of cells may not even be limited to integrins.  One 
particular group has suggested that ATX may be able to interact with certain scavenger 
receptors154 which could provide a link between ATX and lysophospholipids found 
within lipoproteins which also possess ligands for several scavenger receptors.  Given all 
of this, ATX and LPA could play a number of signaling roles in multiple cell types in the 
vasculature and particularly at sites of injury. 
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OVERVIEW OF FINDINGS AND HYPOTHESIZED ROLES IN ATHEROSCLEROSIS 
In Chapter 1, we discussed both the role of platelets and LPA in cardiovascular 
physiology and pathophysiology.  Let us now review progression of atherosclerosis and 
the role that ATX-integrin interaction and cell-specific LPA production might play.  This 
overview is succinctly illustrated in Figure 4.1.  As a resting platelet circulates in healthy, 
uninjured vessels it accumulates certain plasma proteins such as fibrinogen through 
integrin-mediated endocytosis189, 191 and likely accumulates ATX via a similar 
mechanism.  As the platelet approaches an area of vascular damage, interactions with 
the subendothelial matrix induce platelet activation which induces granule secretion of 
a number of proteins including fibrinogen and probably ATX.  Activation also induces an 
increase in PLA activity increasing the amount of lysophospholipids in the extracellular 
leaflet of the lipid bilayer and providing substrate for ATX55.  As integrins on platelets 
and endothelial cells activate, ATX from the plasma and ATX secreted from platelets are 
drawn to the membrane of the integrin-bearing cells thus increasing LPA production and 
localization.  LPA itself acts chemotactically drawing in other cell types such as 
circulating monocytes115.  LPA further facilitates cell recruitment by inducing endothelial 
cells to secrete more chemokines and by increasing the adhesiveness of endothelial 
cells114.  LPA may also facilitate migration of monocytes/macrophages into the 
subendothelium and induce dedifferentiation and proliferation of smooth muscle cells.  
As lipids, particularly LPC, begin to accumulate at the site of injury due to interactions of 
oxLDL with monocyte/macrophage scavenger receptors, this may provide an additional 
concentrated reservoir of substrate for ATX to make use of in addition to what is found 
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in cell membranes.   There are therefore many possible sources of LPA generation 
during a typical response to vascular injury.  Indeed, during a particular injury response, 
not all of the newly produced LPA may even be used for signaling. Rather, much of the 
LPA could actually be stored in high concentrations in the lipid core of an atheroma 
(which indeed is the most thrombogenic component)45.  During plaque rupture, this 
atherosclerotic LPA pool is likely extruded into the plasma and depending on relative 
LPA signaling pathways in platelets may be among the agents that promotes acute 
thrombosis (particularly when coupled with de novo LPA production in platelets and 
other blood cells). 
ROLE OF LPA, ATX, AND INTEGRINS IN OTHER DISEASE STATES 
As stated, the interaction between ATX and integrins would by no means be limited to 
platelets.  Also while this interaction has mostly been discussed in the context of 
cardiovascular disease, it should be noted that disregulation of ATX and integrins likely 
contribute to other disease states.  ATX itself was originally discovered as a glycoprotein 
secreted from a line of human melanoma cells140 and has long been an attractive target 
for anti-cancer therapeutics.  Apart from its ability to promote angiogenesis, LPA can 
also directly induce migration of different cancer cells indicating an additional role in 
regulating cancer motility193-195.  Furthermore LPA levels are elevated in ascites and 
blood of individuals with ovarian cancer, and ATX expression is even enhanced in certain 
cancer cell types196-199.  The role of integrins in cancer has been well established as well.  
Many integrins, particularly αVβ3, show increased expression in a variety of tumors, and 
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their function has been mostly attributed to their role in angiogenesis, their role in 
promoting adhesion-dependent tissue invasion, or their association with growth factor 
receptors200.  Clearly, the facilitation of local LPA production in tumor cells may be an 
additional role that integrins play in cancer progression (especially given overexpression 
of ATX in different cancer types).  Furthermore, platelets themselves have been shown 
to produce LPA in the tumor microenvironment consequently promoting metastasis61.  
Platelets even support the survival of circulating tumor cells and metastasis201, while 
many cancers are associated with a hypercoagulable state202.  The factors involved in 
such interactions are likely multivariable, and could potentially involve ATX/LPA.  In any 
case, the role of an ATX-integrin interaction is an attractive target for future study in a 
number of cancer fields and may even provide novel targets for cancer therapeutics. 
 
 
FINAL COMMENTS 
In conclusion, the work described here clearly describes the role that platelets have in 
LPA production and how the interaction of ATX with integrins not only enhances its 
activity but also localizes LPA production in close proximity to LPA receptors.  We mostly 
investigated this in the context of platelets and further evaluated LPA signaling in 
platelets via the LPA4 and LPA5 receptors.  While the most obvious implications of this 
work relate to cardiovascular health and disease, it is important to recognize that these 
mechanisms of LPA metabolism would not be limited to cells in the cardiovasculature.  
Furthermore, with the increasing appreciation of the role of platelets in other processes 
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aside from hemostasis and thrombosis, platelet LPA may have implications that reach 
into a number of different disease states as well. 
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FIGURE 4.1 
 
Hypothetical Role of ATX-Integrin Interaction in LPA Localization and Atherogenesis.  
ATX is recruited to the surface of platelets and likely other integrin-possessing cells 
including endothelial cells, smooth muscle cells, and leukocytes.  This localization could 
facilitate many of the hallmarks of LPA signaling and indeed the hallmarks of 
atherogenesis including platelet activation, smooth muscle dedifferentiation and 
proliferation, endothelial cell activation, monocyte migration, et cetera.  While we 
hypothesize that the main function of the interaction between ATX and integrin is to 
localize LPA to a specific cell, it is also feasible that LPA could act in a paracrine manner 
on several cell types in close proximity.  Local production of LPA may also be responsible 
for the high levels of this lipid found in the lipid-rich core of atherosclerotic plaques. 
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APPENDIX:  ABBREVIATIONS 
Abbreviation Description 
10E5 Monoclonal antibody that blocks integrin αIIbβ3 
125I Iodine-125 (radioactive isotope 
125I-ATX 125I-labeled ATX 
12G10 Nonblocking monoclonal antibody against β1 integrins 
23C6 Nonblocking monoclonal antibody against integrin αVβ3 
7E3 Monoclonal antibody that blocks β3 integrins 
ADP adenosine diphosphate 
anti-BrP-LPA Anti enantiomer of the bromophosphonate LPA analog 
apoB Apolipoprotein B-100 
APT1 acyl-protein thioesterase 1 
ATX Autotaxin 
ATX-E109A Point mutation of the SMB1 domain of ATX 
ATX-H117A Point mutation of the SMB1 domain of ATX 
ATX-R117A Point mutation of the SMB1 domain of ATX 
ATX-T210A Catalytically inactive point mutation of ATX (threonine in catalytic 
site mutated to alanine) 
AYPGKF Peptide sequence for a PAR4 receptor agonist 
BrP-LPA Racemic mixture of the bromophosphonate LPA analog 
C17 LPA Unnatural LPA species with an acyl chain of 17 carbons 
C17 LPC Unnatural LPC species with an acyl chain of 17 carbons 
C17 S1P Unnatural S1P species with radyl chain of 17 carbons 
cAMP Cyclic adenosine monophosphate 
CHO Chinease hmaster ovary 
DAG Diacylglycerol 
DTT Dithiothreitol  
EDGx Endothelial cell differentiation gene receptor (x denotes numerical 
identity) 
eNOS Endothelial nitric oxide synthetase 
ENPP Ectonucleotide pyrophosphatase/phosphodiesterase 
ENPPx Enzymes of the ectonucleotide pyrophosphatase phosphodiesterase 
family (x denotes numerical identity; ATX is further denoted ENPP2) 
F2Y720 S1P mimetic drug (fingolimod) 
FcγRII Fc gamma receptor 
FITC Fluorescein isothiocyanate 
GP Glycoprotein 
GPCR G protein-coupled receptor 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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LCAT Lecithin cholesterol acyltransferase 
LDL Low-density lipoprotein 
LM609 Monoclonal antibody that blocks integrin αVβ3 
LPA Lysphosphatidic acid 
LPAx Lysophosphatidic acid receptor (x denotes numerical identity) 
LPC Lysophosphatidylcholine 
LPPx Lipid phosphate phosphatase  (x denotes numerical identity) 
LY204002 PI3-kinase inhibitor 
lysoPLD Lysophospholipase D 
MAG Monoacylglycerol 
MRS-2719 P2Y1 receptor inhibitor 
NO Nitric oxide 
NUC Nuclease-like domain of ATX 
oxLDL Oxidized low-density lipoprotein 
P2Yx Purinergic receptors type 2Y (x deontes numerical identity) 
P4C10 Monoclonal antibody that blocks β1 integrins 
PAR Protease-activated receptor 
PBS Phosphate-buffered saline 
PC Phosphoatidylcholine 
PDE Phosphodiesterase domain of ATX 
PF4 Platelet factor 4 
PGI2 Prostaglandin I2 
PKI 14-22 Protein kinase A inhibitor 
PLAx Phospholipase A (X = 1 or 2 and indicates activity at acyl at the sn-1 
position or sn-2 position) 
PPAR Peroxisome proliferator-activated receptor 
PPP Platelet-poor plasma 
PRP Platelet-rich plasma 
RGD Integrin binding peptide sequence (arginine-glycine-aspartic acid) 
S1P Sphingosine 1-phosphate 
S1Px Sphingosine 1-phosphate receptor (x denotes numerical identity) 
shRNA Small hairpin ribonucleic acid 
SMBx Somatomedin B-like domain of ATX (x = 1 or 2) 
Sphkx Sphingosine kinase (x denotes numerical identity) 
syn-BrP-LPA Syn enantiomer of the bromophosphonate LPA analog 
TAG Triacylglyceride 
TGF-β Transforming growth factor β 
TRITC Tetramethyl Rhodamine Iso-Thiocyanate 
TXA2 Thromboxane A2 
vWF von Willebrand Factor 
Y27632 Rho kinase inhibitor 
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